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SUMMARY
Soil-transmitted helminths (STHs) collectively infect one fourth of all human beings, and themajority of livestock in the devel-
oping world. These gastrointestinal nematodes are the most important parasites on earth with regard to their prevalence in
humans and livestock. Current anthelmintic drugs are losing their eﬃcacies due to increasing drug resistance, particularly in
STHs of livestock and drug treatment is often followed by rapid reinfection due to failure of the immune system to develop a
protective response. Vaccines against STHs oﬀer what drugs cannot accomplish alone. Because such vaccines would have to
beproducedonsucha large scale, andbecost eﬀective, recombinant subunitvaccines that includeaminimumnumberofproteins
produced in relatively simple and inexpensive expression systems are required. Here, we summarize all of the previous studies
pertaining to recombinant subunit vaccines for STHs of humans and livestock with the goal of both informing the public of just
how critical these parasites are, and to help guide future developments.We also discuss several key areas of vaccine development,
which we believe to be critical for developing more potent recombinant subunit vaccines with broad-spectrum protection.
Key words: soil-transmitted helminths, anthelmintics, vaccines, adjuvants, protective immunity.
INTRODUCTION
Helminths (animal parasitic nematodes or round-
worms) have debilitated human beings over the
course of evolution, whether infecting our livestock,
our pets, or us directly. Soil-transmitted helminths
(STHs; Table 1) establish chronic infections
within the gastrointestinal (GI) tract and are by far
the most prevalent. The World Health Organization
(WHO) currently estimates that STHs infect 24% of
the human population, and infection causes extensive
morbidity (Bethony et al. 2006). Almost 900 million
children are chronically infected, causing stunted
growth and delayed cognitive and intellectual devel-
opment. Millions of pregnant women are also
infected, leading to adverse birth outcomes.
Although highly concentrated in developing coun-
tries of sub-Saharan African, Southeast Asia and
tropical regions of Central and South America,
those who travel to and from endemic regions are
also at risk of getting infected (Bethony et al.
2006). Furthermore, when also considering the
worldwide prevalence and severity of STHs in live-
stock (Krecek and Waller, 2006), some of which are
known to cause zoonoses (McCarthy and Moore,
2000), greatly reducing the prevalence of these
parasites from earth is critical for future global
human health and economic growth.
It is generally accepted that vaccines for STHs
would be the most ideal control agents as they
would prevent re-infection, which anthelmintic
drugs do not. However, there are no licensed vac-
cines. Currently, chemotherapy is delivered via
mass drug administration (MDA), stirring grave
concern for the strong selection of drug resistance,
especially with limited eﬃcacious anthelmintic
drugs (Geerts and Gryseels, 2001). Immunity to
STH infections does not develop upon clearance,
and represents a vast issue for humans who are
rapidly re-infected after chemotherapy (Bethony
et al. 2006). Thus, vaccines would go a long way
towards STH elimination.
An important distinction between STH infections
in humans and livestock, ruminants in particular, is
that in the latter, protective immunity often devel-
ops with age, but in the former, this is not the
case. So, although the duration of vaccine-induced
protection in livestock may only need to last long
enough to protect younger animals, for humans
this protection would need to last throughout their
lifetime. Thus, developing vaccines for humans
will likely be a much greater challenge than for live-
stock due to the high likelihood that repeated immu-
nizations will be needed throughout life.
What level of eﬃcacy is needed to justify inclusion
of an STH vaccine in a control program? Bartsch
et al. (2016) developed a target product proﬁle
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(TPP) for a recombinant subunit vaccine against
human hookworms and evaluated the vaccines eco-
nomic and epidemiologic impact on hookworm
infection in endemic Brazil. A modelled human
hookworm vaccine administered in a single dose to
infants (78% coverage rate) with an eﬃcacy of 80%
at preventing L3 maturation and providing at least
10 years of protection with a single booster at 15
years of age (78% compliance), and costing $1 per
dose, was highly cost-eﬀective and economically
dominant compared with no intervention or annual
MDA (Bartsch et al. 2016). Thus, a human STH
vaccine with such a TPP should be ideal.
For livestock, a subunit vaccine called Barbervax,
developed in Australia, has been commercialized for
Haemonchus contortus (barber’s pole worm) that con-
sists of a complex combination of native antigens
from the worm’s gut (described in more detail
below). Barbervax is about 70% eﬀective at reducing
worm burdens and about 90% eﬀective at reducing
the number of eggs in the feces, which greatly
reduces egg numbers throughout the pasture, and
thus, the number of infections later on. Barbervax
is much more cost-eﬀective and eﬃcacious
compared with no intervention and MDA alone
(especially considering rampant anthelmintic drug
resistance in H. contortus) even though it has to be
given repeatedly during the summer months (when
infection is highest) because a protective memory
response is not induced in vaccinated lambs during
challenge infection. Clearly any STH vaccine for
livestock with such a high eﬃcacy would meet the
requirements of an established TPP. As Barbervax
is not a recombinant subunit vaccine, it requires
numerous sheep to make enough worm guts to
produce the vaccine. It is hard to tell if recombinant
subunit vaccines for livestock should have similar
TPPs and this will have to be addressed in the
future.
There have beenmany attempts to develop vaccines
for STHs of humans and livestock (Hewitson and
Maizels, 2014). These parasites are relatively large,
multicellular, cuticularized animals (i.e. unique from
other infectious agents). They have relatively large
genomes and produce many thousands of oﬀspring
per day, contributing to their rapid evolution
(Zarowiecki and Berriman, 2015). It is thus clear
that the biology of these parasites provides a
Table 1. Biology of soil-transmitted helminth (STH) infections in humans and livestock
STHa,b Principle host(s)
GI tract
location
Ingested host
contents Common sequelae
Ancylostomatidae (hookworms)
N. americanus (Na)c Humans SI Blood Blood loss; anaemia; protein
malnutrition
A. duodenale Humans SI Blood Blood loss; anaemia; protein
malnutrition
A. ceylanicum (Acey)c Dogs; cats; humans SI Blood Blood loss; anaemia; protein
malnutrition
A. caninum (Ac) Dogs; catsd SI Blood Blood loss; anaemia; protein
malnutrition
Strongyloides spp.
S. stercoralis (Ss)c Humans; dogs; cats SI Intestinal ﬂuid Mostly asymptomatic
S. fuelleborni Humans SI Intestinal ﬂuid Mostly asymptomatic
Trichostrongylidae
H. contortus (Hc)c Sheep; goats Abomasum Blood Blood loss; anaemia; oedema
O. ostertagi (Oo) Cattle Abomasum Abomasal contents Severe diarrhoea
T. circumcincta (Tci) Sheep; goats Abomasum Abomasal contents Severe diarrhoea
Ascaridae (Ascarids)
A. lumbricoides Humans SI Luminal contents Mostly asymptomatic
A. suum (As)c Pigsd SI Luminal contents Mostly asymptomatic
T. canis Dogs SI Luminal contents Mostly asymptomatic
T. cati Cats SI Luminal contents Mostly asymptomatic
B. schroederi (Bs) Giant pandas SI Luminal contents Relatively high mortality rate
B. procyonis Raccoonsd SI Luminal contents Mostly asymptomatic
Trichurids (whipworms and Trichinella)
T. trichiurac Humans LI Mucus; blood? Abdominal pain; bloody diarrhoea
T. spiralis (Ts)c Pigs; horses;
dogs; catsd
Muscle; SI Intestinal ﬂuid Abdominal pain; diarrhoea
GI, gastrointestinal; SI, small intestine; LI, large intestine.
a Only the STHs that are mentioned in this review and infect humans or livestock (or in the case of B. schroederi
endangered wild animal species) are listed.
b Only STH species from which the immunogens in Table 2 are derived from given abbreviations in parentheses.
c Genome has been sequenced.
d Relatively frequent reported transmissions from principle host(s) to humans.
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formidable barrier for vaccine development. Also,
although ‘holistic’ vaccines [radiation-attenuated
larvae, crude worm extracts and excretory/secretory
(ES) products] have provided high levels of protec-
tion against many STHs tested, with a few STHs
of livestock being some exceptions (Hewitson and
Maizels, 2014), because these parasites cannot be
cultured on a large enough scale for mass vaccine
administration (unlike bacteria and viruses) due to
high costs, low stability and shelf-life, among other
reasons, recombinant subunit vaccines are necessary.
Hence, in this review we do not evaluate the previous
vaccine studies that used ‘holistic’ vaccines as this
has been extensively reviewed before (Hewitson
and Maizels, 2014). Rather, we provide an update
and evaluation of the previous studies that used
recombinant subunit vaccines, the only realistic
type of vaccine possible for controlling STHs.
Below, we ﬁrst provide a general overview of the
immune response(s) that are most relevant for this
review. We then summarize and interpret the previ-
ous studies that used recombinant subunit vaccines
for the major STHs of both humans and livestock
(data presented in Table 2), grouped into separate
sections based on their phylogenetic relationships
(Blaxter and Koutsovoulos, 2015). In this review,
we use the phylogeny of Nematoda that groups the
phylum into ﬁve distinct clades (clades I, II, III,
IV and V), of which the parasitic species relevant
for human and veterinary medicine belong to
clades I, III and V (Blaxter and Koutsovoulos,
2015). Included in each section is a brief description
of each STH’s basic biology to compare and contrast
with the other STHs. We then provide an evaluation
of all of these studies as a whole, and discuss poten-
tial avenues that may help to develop more eﬃca-
cious, recombinant subunit vaccines for these
critical parasites.
TH1 and TH2 immune responses
Two key arms of the adaptive immune system are
the type 1 and type 2 T helper (TH) cell responses
(TH1 and TH2) (Romagnani, 2000). The TH1
response promotes cell-mediated immunity, while
TH2 promotes humoral immunity. Whether a TH1
or TH2 response is induced generally depends on
whether the pathogen is intracellular (such as
viruses, and some bacteria and protozoa), or extra-
cellular, such as helminths, and also toxins.
However, it must be noted that many cracks have
been discovered in the foundation for the TH1/
TH2 paradigm, in particular that the abundance of
eﬀector cytokines, chemokines, co-stimulatory
molecules, signalling pathways and transcription
factors involved in each response is much greater
and more complex than originally thought (Zhu
et al. 2010), and there appear to be variations of
these responses for particular pathogen types. ButrB
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for the purpose of this review, we will only mention
how TH1 and TH2 responses are mounted, brieﬂy
summarizing that covered in Kaiko et al. (2008).
We begin with the TH1 response. Host cells (non-
professional antigen presenting cells or APCs)
infected with intracellular pathogens present anti-
gens via Class I Major Histocompatibility
Complex (MHC) molecules. Cognate naïve CD8+
cytotoxic T (TC) cells then recognize the antigen-
bound Class I MHC via the antigen-speciﬁc T cell
receptor (TCR), resulting in the activation and
diﬀerentiation of TC cells into antigen-speciﬁc
eﬀectors that destroy the infected cell, or into
memory TC cells for responding to future cognate
antigen. Professional APCs such as macrophages or
dendritic cells also recognize and endocytose the
pathogen or its antigens and present them on Class
II MHC molecules. The antigen-loaded profes-
sional APCs then travel to nearby lymphoid tissues
where they are recognized by cognate naïve CD4+
TH (TH0) cells via antigen-speciﬁc TCR. In com-
bination with the cytokine interleukin (IL)-12
secreted by the professional APCs and necessary
co-stimulatory molecules (‘signal two’ and ‘signal
three’), TH0 cells diﬀerentiate into TH1 eﬀector cells
that proliferate and produce massive quantities of
pro-inﬂammatory cytokine interferon gamma (IFN-
γ), as well as IL-2 and tumour necrosis factor
(TNF), triggering the inﬂux of inﬂammatory cells
and the complement system into the site of infection,
or into TH1 memory cells. TH1 eﬀector cells also
provide help to diﬀerentiating TC cells and induce B
cell-secretion of opsonizing antibodies or immunoglo-
bulins (Ig), in general IgG2, which along with the
complement system enhances phagocytosis, and
thus, pathogen clearance (Kaiko et al. 2008).
When professional APCs present antigens from
extracellular pathogens such as helminths, or
toxins/allergens, to TH0 cells in lymphoid tissues,
the professional APCs secrete IL-2 and IL-4 that,
along with the necessary co-stimulators, drives
diﬀerentiation of TH0 cells into TH2 eﬀectors or
into TH2 memory cells. TH2 eﬀector cells secrete
three key cytokines that drive classic features of the
TH2 response, IL-4, IL-5 and IL-13. They can
also secrete IL-10, which tends to dampen immune
responses. IL-4: (1) drives antibody class switching
from IgM to IgG1 and IgE; (2) drives aﬃnity mat-
uration by somatic hypermutation in B cells; (3) sti-
mulates B cell proliferation and diﬀerentiation into
plasma cells; and (4) drives diﬀerentiation of TH2
cells, thus providing feedback regulation. IL-5
attracts and activates eosinophils, and also drives
the secretion of IgA (Lebman and Coﬀman, 1988),
the most abundant mucosal antibody responsible
for intestinal homoeostasis (Mantis et al. 2011).
IL-13 mediates the release of granules from baso-
phils and mast cells and can also drive class switch-
ing to IgE. In TH2-mediated allergy, IgE is key,
with the Fcε region of the heavy chain recognized
with high aﬃnity by the FcεRI receptor that is con-
stitutively expressed on basophils and mast cells.
This receptor is expressed at much lower levels on
professional APCs and is inducible on eosinophils.
Basophils, mast cells and eosinophils are granulo-
cytes that collectively release proinﬂammatory med-
iators and cytotoxins that result in a robust,
hypersensitivity reaction associated with allergy
(Kaiko et al. 2008; Stone et al. 2010).
TH2-type responses are clearly associated with
reduced intensities of infection by STHs (Anthony
et al. 2007; Nair and De’Broski, 2016). These
responses involve an interconnected, complex
network of IgE-driven mastocytosis and basophilia,
IL-5-driven eosinophilia, and IL-4/IL-13-driven
alternative activation and recruitment of macro-
phages and parasite expulsion. Expulsion occurs
via intestinal epithielial cell (IEC) secretion of
RELM-β and Muc2/Muc5ac (‘mucus’), IEC turn-
over (‘epithelial escalation’) and/or increased IEC
permeability and smooth muscle contraction
(‘weep and sweep’ response) (Anthony et al. 2007;
Nair and De’Broski, 2016). However, subunit vac-
cines do not necessarily need to induce the natural
immune response(s) in order to provide protection.
Subunit vaccines for STHs have focused primarily
on the idea that the protein antigens targeted by
the vaccines are important for infection, rather
than simply being immunogenic in order to direct
the immune system to the pathogen to attack it.
Immunization with most STH antigens triggers
IgG responses (IgG1 and IgG2 are by far the most
abundant serum antibodies), although titre is
highly variable. The common theme is that high
IgG titre blocks antigen function, and if the
antigen is essential, protection may be achieved. As
discussed below, the most promising vaccine candi-
dates discovered from previous studies are consistent
with this common theme.
RECOMBINANT SUBUNIT VACCINES FOR
STRONGYLIDS
The order Strongylida (Nematoda clade V) contains
many important parasitic species, including devas-
tating parasites of humans, livestock, dogs and
cats, as well as species that infect birds, reptiles and
amphibians (Durettedesset et al. 1994). Strongylida
was once grouped into four suborders: Strongylina,
Ancylostomatina, Trichostrongylina and Metastro-
ngylina, of which the former three suborders con-
tained the most signiﬁcant species for human and
veterinary medicine (Durettedesset et al. 1994).
But it is now clear that these suborders are not
monophyletic and that the most signiﬁcant species
within the former three suborders are actually in
their own monophyletic group (Chilton et al.
2006). Thus, we do not use the suborders in this
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review, but only refer to the most relevant families,
which are currently stable. The most extensive
studies with recombinant subunit vaccines for stron-
gylids have been on hookworms, with studies on
Strongyloides spp. and a few strongylid parasites of
livestock also prevalent in the literature. As many of
the important strongylid species within these families
have relatively recent common ancestries with very
similar modes of infection (Durettedesset et al. 1994;
Chilton et al. 2006; Blaxter and Koutsovoulos, 2015),
a single, pan-strongylid vaccine with eﬃcacy against a
majority of the species seems within reason, hence
why we have grouped them into their own section.
Hookworms
Hookworms (family Ancylostomatidae) are a serious
issue for human health, as well as for dogs and cats,
and of all the STHs, these parasites cause the most
severe disease due to their voracious blood feeding
(Table 1). The human hookworms (Necator ameri-
canus, Ancylostoma duodenale and Ancylostoma cey-
lanicum) infect almost 500 million people (Pullan
et al. 2014). Necator americanus and A. duodenale
infect predominantly humans while A. ceylanicum
infects humans, dogs, cats and some rodents.
Third stage larvae (L3) penetrate the skin and
enter the blood stream, arriving in the lungs for L3
maturation (N. americanus and Ancylostoma spp.).
L3 then migrate up the trachea into the pharynx
and are swallowed. Ancylostoma spp., but not
Necator, are also able to directly enter orally. After
passing through the stomach, L3 burrow into the
epithelium of the small intestine, most often in the
duodenum, and rupture capillaries to feed on
blood. Blood feeding by the attached hookworms
causes iron deﬁciency anaemia in humans, and is of
major concern for children and pregnant women.
Adult hookworms mate within the lumen of the
small intestine, and each female can produce over
10 000 eggs per day. These hematophagous parasites
can live for years in the same host (Hotez et al. 2004).
Pre-clinical vaccine studies for hookworms have
either used the dog hookworm Ancylostoma caninum-
beagle or A. ceylanicum-golden hamster (Mesocricetus
auratus) pathosystems, or a laboratory strain of
N. americanus adapted to golden hamsters. Antigens
from both infectious L3 and adult hookworms have
been subjected to pre-clinical vaccine studies. These
past attempts focused on recombinant subunit
vaccines using Escherichia coli, Pichia pastoris or
baculovirus-insect cell expression systems.
Secreted L3 antigens. Beagles that received four
intramuscular (i.m.) injections at 140 µg each of a
recombinant, E. coli-expressed Astacin-like metallo-
protease (rAc-MTP-1), natively secreted by L3, and
formulated with GlaxoSmithKline’s AS02 adjuvant
(TH1-biased) in general had lower A. caninum worm
burdens and fecal egg counts (FECs) compared with
AS02 alone [Table 2; the level of protection was cor-
related with serum IgG2 endpoint titre (i.e. the
inverse of the greatest serum dilution at which
there is an above background response)] (Hotez
et al. 2003). This initial study provided proof of
concept that recombinant subunit vaccines have
eﬃcacy against hookworms.
Ancylostoma secreted protein (Ac-ASP-2) is
natively expressed in the oesophageal gland cells,
basal lamina and cuticle, and secreted by L3.
Baculovirus-insect cell-expressed rAc-ASP-2 for-
mulated with GlaxoSmithKline’s AS03 adjuvant
(unresolved TH response) and injected i.m. four
times into beagles at 100 µg doses had average
serum IgG1 and IgG2 endpoint titre of >10 000
and average serum IgE endpoint titre of 1000
(Table 2). rAc-ASP-2/AS03 immunization resulted
in an average 26 and 69% lower A. caninum worm
burdens and FECs, respectively, compared with
AS03 alone (Table 2), although the latter measure
had extensive variation. Interestingly, in the same
study, intensity ofN. americanus infection in indivi-
duals from endemic Brazil was negatively correlated
with IgE titre speciﬁc for Na-ASP-2, revealing this
L3 antigen as naturally immunogenic and, possibly,
naturally protective.
In another study, P. pastoris-expressed rAcey-
MTP-1 and rAcey-ASP-2 were injected three
times i.m. into golden hamsters at 25 µg doses as
both monovalent and bivalent vaccines formulated
with Quil-A adjuvant (mixed TH1/TH2 response).
Immunization resulted in impressive average total
serum IgG endpoint titre (no IgG subclass-speciﬁc
secondary antibodies for hamsters) between 50 000
and 200 000, including from both the monovalent
and bivalent vaccines (Table 2), suggesting that
immunological interference was not a problem.
Similar to that found in the A. caninum-beagle
pathosystem, both monovalent vaccines resulted in
lower A. ceylanicum FECs (rAcey-ASP-2/Quil-A =
56% lower; rAcey-MTP-1/Quil-A = 43% lower)
and worm burdens (rAcey-ASP-2/Quil-A = 32%
lower; rAcey-MTP-1/Quil-A = 28% lower) com-
pared with Quil-A alone, although the worm
burden for rAcey-MTP-1/Quil-A were not signiﬁ-
cantly less (Table 2). Surprisingly, the bivalent
vaccine did not provide signiﬁcant, additive protec-
tion over the monovalents with an average 59 and
36% lower FECs and worm burdens, respectively,
compared with Quil-A alone (Table 2). On the
other hand, clinicopathological parameters (reduced
haemoglobin and body weight) were signiﬁcantly
improved in the bivalent compared with the mono-
valent vaccines (Table 2) (Mendez et al. 2005).
Nonetheless, lack of a signiﬁcant additive eﬀect on
FECs and worm burdens suggests that ASP-2 and
MTP-1 may have functional redundancies during
tissue migration.
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Ac-16 is homologous to larval surface antigens of
Nematoda clade III helminths that had been previ-
ously shown to protect against experimental infec-
tions (see section on ascarids below). Ac-16 was
expressed in E. coli, formulated with AS03 and
injected three times i.m. into beagles at 100 µg
doses. Immunization of beagles with rAc-16/AS03
resulted in peak serum IgG1, IgG2 and IgE end-
point titre of around 5000, 100 000 and 1000,
respectively, signiﬁcant rAc-16-stimulated prolifer-
ation of peripheral blood cells and production of
IFN-γ, but not IL-4 or IL-10 (Table 2). rAc-16/
AS03 also resulted in an average 63% lower A.
caninum FECs and signiﬁcantly less blood loss
compared with AS03 alone, but worm burdens
were similar (Table 2) (Fujiwara et al. 2007).
Nonetheless, this study clearly demonstrated the
vaccine eﬃcacy of rAc-16/AS03 for reducing hook-
worm fecundity and hookworm-associated blood
loss, in association with IgG and IgE responses,
and a TH1-biased cytokine proﬁle (but without
measuring IL-5 and IL-13, contribution from at
least some TH2 cytokines cannot be ruled out). Ac-
16 was also localized to the L3 cuticle with rAc-16/
AS03 serum from beagles (Fujiwara et al. 2007).
With the promising pre-clinical results for ASP-2
(signiﬁcantly reduced worm burdens, FECs and
clinical pathology), and negative correlation between
infection intensity and Na-ASP-2-speciﬁc serum
IgE responses in individuals from endemic Brazil,
P. pastoris-expressed rNa-ASP-2 formulated on
Alhydrogel (aluminum hydroxide gel; a widely
used TH2 adjuvant) (Goud et al. 2005) advanced to
clinical trials. Three i.m. injections in healthy and
unexposed adults of either 10, 50 or 100 µg doses
were well tolerated and induced total serum IgG
endpoint titre of around 10 000, while serum IgE
endpoint titre were below 100, and signiﬁcant rNa-
ASP-2-stimulated proliferative responses in periph-
eral blood mononuclear cells (PBMCs) (Table 2)
(Bethony et al. 2008). However, rNa-ASP-2/
Alhydrogel in only a single injection of 10 µg failed
in Phase I as individuals previously infected with
or exposed to N. americanus resulted in generalized
urticarial reactions due to pre-existing Na-ASP-2-
speciﬁc serum IgE (Table 2) (Diemert et al. 2012).
Although rNa-ASP-2 is still being optimized to
reduce its allergic potential, namely by removing
the IgE epitopes and fusion with Fcγ1, thus promot-
ing its ligation with the FcγRIIb inhibitory receptor
(Zhan et al. 2012), these ﬁndings have halted vaccine
studies focused on L3 antigens.
Adult intestinal antigens. Results with ASP-2
demonstrated an important problem for targeting
antigens that are naturally immunogenic during
hookworm infection (at least from L3); there may
be an allergic reaction following immunization of
individuals that had been previously infected or
exposed. Thus, next attempts focused on the so-
called ‘hidden antigens’ (i.e. STH proteins that are
not exposed to the host immune system during
infection but that may be accessed by host immune
eﬀectors induced by vaccination) present in the
hookworm intestinal lumen and thus accessible to
host antibodies in the ingested blood (Hotez et al.
2010). Hookworms have a semi-ordered proteolytic
cascade in their intestinal lumen for digesting
haemoglobin during blood meals (Williamson et al.
2004; Ranjit et al. 2009) and all of the vaccine
studies pertaining to adult intestinal antigens have
focused on this process (Hotez et al. 2010).
A recombinant, P. pastoris-expressed, Cathepsin
B cysteine protease (rAc-CP-2) that natively loca-
lizes in the hookworm intestinal lumen (Loukas
et al. 2004) and that degrades fragments of haemo-
globin in vitro (Williamson et al. 2004; Ranjit et al.
2009), was formulated with multiple adjuvants
[AS02, AS03, ISA70 and aluminium phosphate
(alum)] and injected i.m. three times into beagles
at 100 µg doses (Loukas et al. 2004). Although rAc-
CP-2/adjuvant immunizations resulted in average
serum IgG1 and IgG2 endpoint titre of >10 000
and average serum IgE endpoint titre of around
1500 regardless of adjuvant, A. caninum worm
burdens were the same as adjuvant controls, while
FECs were an average 60% lower (Table 2). The
lowest FECs and highest IgG titre were observed
with the AS03 adjuvant, although the diﬀerences
from the other adjuvants were not signiﬁcant. Also,
pooled IgGs from rAc-CP-2/AS03-immunized
beagles reduced the in vitro rAc-CP-2 protease activ-
ity by an average of 73% and recognized native Ac-
CP-2 within the adult hookworm intestinal lumen
(Loukas et al. 2004), suggesting that blocking/neu-
tralizing IgG contributed to the reduced fecundity.
Another adult antigen, Cathepsin D aspartic pro-
tease (Ac-APR-1), which is also localized within the
intestinal lumen but degrades whole haemoglobin
(Williamson et al. 2004; Ranjit et al. 2009), was
recombinantly expressed in P. pastoris. rAc-APR-1
was formulated with AS03 and injected i.m. three
times in 100 µg doses into beagles. rAc-APR-1/
AS03 immunization resulted in average serum
IgG1 and IgG2 endpoint titre of >10 000 and
average serum IgE endpoint titre of around 1500
(Table 2). There was signiﬁcant IFN-γ production
and proliferative responses in rAc-APR-1-stimu-
lated whole blood cells (Table 2). rAc-APR-1/
AS03 immunization resulted in 70 and 33% lower
median A. caninum FECs and worm burdens,
respectively, and anaemia was signiﬁcantly less com-
pared with AS03 alone (Table 2). Similar to rAc-
CP-2/AS03, serum IgG from beagles immunized
with rAc-APR-1/AS03 reduced the in vitro protease
activity of rAc-APR-1 by an average of 71%, and
recognized native Ac-APR-1 within the adult hook-
worm intestinal lumen (Loukas et al. 2005).
1852Jason B. Noon and Raﬃ V. Aroian
https://www.cambridge.org/core/terms. https://doi.org/10.1017/S003118201700138X
Downloaded from https://www.cambridge.org/core. The Lamar Soutter Library, on 24 Jan 2018 at 20:00:47, subject to the Cambridge Core terms of use, available at
The ﬁnal protective adult hookworm antigen is a
glutathione S-transferase (GST-1) that is localized
within the intestine, muscular tissue and hypoder-
mis and is also present in adult excretory/secretory
(ES) products. GST-1 is believed to scavenge and
detoxify haeme liberated from degraded haemoglo-
bin within the hookworm intestine (Zhan et al.
2005). Based on GST-1’s localization in the hypo-
dermis and presence in ES products, the protein
may have other functions as well. Pichia pastoris-
expressed rAc-GST-1/AS03 i.m. injections into
beagles (three times in 100 µg doses), as with rAc-
CP-2/AS03 and rAc-APR-1/AS03, resulted in
average serum IgG1 and IgG2 titre of >10 000,
lower average serum IgE endpoint titre of <500,
and signiﬁcant proliferative responses and IFN-γ
production in rAc-GST-1-stimulated whole blood
cells (Table 2). rAc-GST-1/AS03 immunization
resulted in an average 32 and 39% lower A.
caninum FECs and worm burdens, respectively,
compared with AS03 alone (Table 2). These reduc-
tions were not signiﬁcant, which was attributed to
too much variation between beagles. However, in
the same study, rAc-GST-1 formulated on
Alhydrogel was subcutaneously (s.c.) injected three
times at 25 µg doses into golden hamsters and chal-
lenged with the adapted laboratory N. americanus
strain, and worm burdens were a signiﬁcant 54%
lower than Alhydrogel alone (Table 2) (Zhan et al.
2005). Although immune correlates of this protec-
tion were not evaluated, this result provided proof
of concept for cross-protection against hookworms
from diﬀerent genera using the same immunogen,
in addition to revealing GST-1 as a promising
vaccine target.
In another study using the N. americanus-golden
hamster pathosystem, rAc-GST-1/Alhydrogel under
the same immunization regimen as Zhan et al. (2005)
again had an average of 51% lower N. americanus
worm burdens, and in the same study, rAc-APR-1/
Alhydrogel had 44% lower N. americanus worm
burdens compared with Alhydrogel alone (Table 2)
(Xiao et al. 2008).Thus, bothA. caninum immunogens
were capable of cross protecting againstN. americanus
in golden hamsters, although immune correlates of
protection were not evaluated.
The cross-protections against N. americanus in
golden hamsters with rAc-GST-1/Alhydrogel and
rAc-APR-1/Alhydrogel are the greatest reported to
date compared with any other recombinant subunit
vaccines against hookworms. A recombinant bivalent
subunit vaccine containing rNa-GST-1 expressed in
P. pastoris and a catalytically inactive, but still
immunogenic (Pearson et al. 2009), rNa-APR-1
expressed in tobacco plants (used as an alternative to
P. pastoris since expression was low) and formulated
on Alhydrogel is currently in Phase I clinical trials
(Hotez et al. 2016). Clinical testing is also evaluating
if including synthetic Toll-like receptor agonists
glucopyranosyl lipid A (GLA) or CpG oligodeoxynu-
cleotide will help achieve acceptable immunogenicity
(Hotez et al. 2016). Surprisingly, to the best of our
knowledge there are no published results on the
level of protection provided by the bivalent vaccine.
Some important questions remaining to be addressed
are whether there is an additive or maybe synergistic
eﬀect when combining rAPR-1 and rGST-1, or
rather, no additive eﬀect, similar to that observed for
the rAcey-ASP-2/rAcey-MTP-1 bivalent (Mendez
et al. 2005). Given that both APR-1 and GST-1 are
assumed to function in haemoglobinolysis (Hotez
et al. 2010), it seems reasonable to suspect redundancy
in blocking/neutralizing both antigens. For example,
blocking/neutralizing APR-1 would in theory
prevent liberation of heme since haemoglobin would
no longer be broken down, thereby making GST-1
redundant. Moreover, adult hookworms can survive
in vitro in serum alone, so it is likely that haemoglobin
is not the only source of protein in their diet within the
intestine. Nevertheless, this vaccine is admittedly not
expected to prevent hookworms from establishing
infection within the small intestine (Hotez et al.
2010; Hotez et al. 2016), but the evidence does
suggest that it will reduce clinicopathological para-
meters below threshold levels. Thus, although there
are still many unanswered questions for this vaccine,
there is cautious optimism for signiﬁcant impact.
DNA vaccines. More recently, a pair of studies
used a DNA vaccine approach against A. ceylanicum
in golden hamsters (Wisniewski et al. 2013, 2016).
With a DNA vaccine, the antigen’s cDNA is
cloned into a plasmid vector and then the plasmid
is injected into the host with the expectation that it
will enter host cell nuclei for transcription and will
subsequently be translated in the host cell cytoplasm.
In the ﬁrst study, A. ceylanicum metalloprotease 6
(Acey-MEP-6) cDNA (a likely adult intestinal
antigen) was cloned into the plasmid vector
pcDNA3·1+, mixed with Fugene 6 Transfection
Reagent (presumably to enhance uptake into host
cells), and administered intranasally (i.n.) both once
and three times in 50 µg doses into golden hamsters.
Single dose pcDNA3·1+/Acey-MEP-6/Fugene 6,
but not triple dose, resulted in signiﬁcantly lower A.
ceylanicum worm burdens and signiﬁcantly higher
haematocrit compared with golden hamsters receiving
no vaccine, but not compared with golden hamsters
receiving either single or triple doses of pcDNA3·1
+/Fugene 6 (empty vector/transfection reagent)
control (Table 2) and immune responses were not
evaluated (Wisniewski et al. 2013). Thus, although
pcDNA3·1+/Acey-MEP-6/Fugene 6 appeared to
have some vaccine eﬃcacy, the clear impact that
the empty vector/transfection reagent control had
onA. ceylanicum challenge infection and lack of eval-
uated immune correlates of protection makes it
diﬃcult to interpret these results.
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In a follow up study with an Acey-MEP-7 cDNA
(paralog of Acey-MEP-6), single dose pcDNA3·1
+/Acey-MEP-7/Fugene 6 (amount of plasmid was
not reported) resulted in signiﬁcantly lowerA. ceyla-
nicum worm burdens and FECs, and signiﬁcantly
higher post-challenge hematocrit compared with
pcDNA3·1+/Fugene 6 control in golden hamsters
(Table 2) (Wisniewski et al. 2016). Also, pcDNA3·1
+/Acey-MEP-7/Fugene 6 resulted in signiﬁcantly
greater rAcey-MEP-7-speciﬁc total serum IgG
responses (measured as optical density at 450 nm;
OD450) compared with pcDNA3·1+/Fugene 6
control, although the diﬀerence was not great (average
OD450 of ∼0·7 compared with ∼0·4) (Table 2)
(Wisniewski et al. 2016). Although this study clearly
indicates signiﬁcant vaccine eﬃcacy of pcDNA3·1
+/Acey-MEP-7/Fugene 6, the issue with the empty
vector/transfection reagent control also having an
eﬀect (Wisniewski et al. 2013) has not been fully
resolved, and immune correlates are weak. Thus,
eﬃcacy of DNA vaccines for hookworms remains
unclear.
Strongyloides spp.
Species within the Strongyloides genus (family
Strongyloididae) have been reported to infect
humans, non-human primates, dogs, cats and some
rodents (Table 1). At least two species, Strongloides
stercoralis and Strongyloides fuelleborni, commonly
infect humans, with a total of approximately 100
million people infected (Puthiyakunnon et al. 2014).
Although symptoms are often subclinical, strongyl-
oidiasis can be deadly in immunosuppressed people
with hyperinfection syndrome. These strongyloid
parasites alternate between free-living and parasitic
cycles. Free-living larvae passed in the stool can
either moult to infectious L3 or can continue a free-
living cycle and ultimately moult to egg-laying adult
worms outside of a host for a single generation (an
advantage in the absence of a suitable host). Similar
to hookworms, in the presence of a suitable host, L3
penetrate the skin and enter the bloodstream where
they undergo maturation in the lungs, followed by
migration up the trachea and into the pharynx where
they are swallowed, ﬁnally developing into adult
worms within tunnels of the small intestine. Eggs
hatch within the small intestine, and larvae are either
excreted with the feces outside of the host, or can
develop to infectious L3 within the small intestine
and immediately reinfect the intestinal mucosa (auto-
infection). Chronic asymptomatic infections can be
maintained in human hosts for decades
(Puthiyakunnon et al. 2014).
DNA vaccines. The ﬁrst study that tested recom-
binant subunit vaccines against Strongyloides spp.
used a DNA vaccine approach against experimental
S. stercoralis L3 infection in BALB/cJ mice
(Kerepesi et al. 2005). Strongloides stercoralis
deoxycholate-soluble L3 antigens tropomyosin
(Ss-TMY-1), Na+-K+ ATPase (Ss-EAT-6) and
galectin (Ss-LEC-5) were shown to be recognized
by serum IgG isolated from human plasma obtained
from exposed Haitian donors, and this serum was
shown to passively transfer protection to BALB/cJ
mice (Kerepesi et al. 2004). Six intradermal (i.d.)
injections of 20 µg doses were performed in the
ears of mice with Lambda Uni-zap XR vector indi-
vidually containing cDNA inserts for all three S.
stercoralis antigens mixed with the plasmid
VC1701 containing murine ganulocyte-macrophage
colony-stimulating factor (GM-CSF). Only
plasmid Ss-tmy-1/GM-CSF and plasmid Ss-eat-6/
GM-CSF resulted in signiﬁcant, synthetic peptide-
speciﬁc total serum IgG responses compared with
control plasmid GM-CSF alone, albeit with very
weak responses (OD450 of ∼0·25 and ∼0·6, respect-
ively, compared to ∼0·15 in control using 1 : 100
serum dilutions) (Table 2). Immunized mice were
challenged s.c. with S. stercoralis L3 in diﬀusion
chambers (i.e. devices with openings that are small
enough to keep the worms inside but large enough
to allow immune cells to enter) for 4 days, and
only plasmid Ss-eat-6/GM-CSF resulted in signiﬁ-
cantly lower L3 survival (35%) within the diﬀusion
chambers compared with plasmid GM-CSF
control (Table 2). However, mice immunized with
a combination of all three DNA vaccines did not
result in signiﬁcantly lower L3 survival compared
with plasmid GM-CSF control (Table 2).
Although triply vaccinated mice had signiﬁcant
total serum IgG responses against Ss-EAT-6 syn-
thetic peptides, these responses were lower than
plasmid Ss-eat-6/GM-CSF alone. Passive transfer
of serum from vaccinated into naïve mice for all
DNA vaccine groups did not result in signiﬁcantly
lower S. stercoralis L3 survival compared with
plasmid GM-CSF control serum, not even for
plasmid Ss-eat-6/GM-CSF, although the latter did
result in the lowest survival (Kerepesi et al. 2005).
Protein vaccines. Ss-TMY-1, Ss-EAT-6 and Ss-
LEC-5, as well as two highly and naturally immuno-
genic S. stercoralis antigens used for diagnostics in
humans [Ss-NEI-1 and Ss-IR; (Ramanathan et al.
2008)] were tested for expression in E. coli, baculo-
virus-insect cells, and the yeast Kluyveromyces
lactis expression systems (Abraham et al. 2011). All
but rSs-TMY-1 expressed well in the baculovirus-
insect cell expression system, while rSs-TMY-1
expressed well in K. lactis. All immunogens were
formulated with alum and injected s.c. twice in 25
µg doses into BALB/cByJ mice. All vaccines resulted
in total serum IgG responses against cognate immu-
nogen (albeit weak; ODs between only 0·5 and 2·0 at
1:100 serum dilutions, with background in controls
around 0·25) (Table 2). Cellular immune responses
1854Jason B. Noon and Raﬃ V. Aroian
https://www.cambridge.org/core/terms. https://doi.org/10.1017/S003118201700138X
Downloaded from https://www.cambridge.org/core. The Lamar Soutter Library, on 24 Jan 2018 at 20:00:47, subject to the Cambridge Core terms of use, available at
were not signiﬁcantly diﬀerent for any of the vaccines,
measured as the number of neutrophils, macrophages
and eosinophils inﬁltrated into diﬀusion chambers
after challenge. Of all the vaccines tested, only
immunization with rSs-IR/alum resulted in signiﬁ-
cantly lower survival of S. stercoralis L3 with an
average 80% lower survival in three diﬀerent trials
compared with alum alone (Table 2). Passive transfer
of serum from mice immunized with rSs-IR/alum
into naïve mice again resulted in an approximately
80% lower L3 survival. Finally, serum from mice
immunized with rSs-IR/alum localized native Ss-
IR within granules of the glandular oesophagus in
immunoelectron microscopy, and on the surface of
S. stercoralis L3 in immunoconfocal microscopy
(Abraham et al. 2011).
Consistent with DNA vaccination (Kerepesi et al.
2005), neither Ss-TMY-1 nor Ss-LEC-5 showed
any evidence of eﬃcacy as recombinant, protein-
based, subunit vaccines (Abraham et al. 2011).
Although the lack of signiﬁcant vaccine eﬃcacy for
Ss-EAT-6 (Abraham et al. 2011) somewhat contra-
dicts its eﬃcacy (albeit low) as a DNA vaccine
(Kerepesi et al. 2005), it was speculated that rSs-
EAT-6 might need a diﬀerent adjuvant to induce
protection. On the other hand, rSs-IR/alum is a
potential candidate whose eﬃcacy as a recombinant
subunit vaccine for strongyloidiasis (Abraham
et al. 2011) in principle could be further investi-
gated. However, the weak IgG response, the lack
of signiﬁcant immune correlates with rSs-IR/alum-
induced protection, and the presence of Ss-IR on
the surface of L3 (potentially risking allergic reac-
tions in clinical trials as was found with rNa-ASP-
2 detailed above) present important hurdles for this
vaccine. Abraham et al. (2011) speculate that the
mechanism of rSs-IR/alum-induced protection
may be through complement and/or antibody-
dependent cellular cytotoxicity (ADCC) as these
mechanisms were demonstrated to be important
for vaccine-induced reduction of S. stercoralis L3
survival (Ligas et al. 2003; Kerepesi et al. 2004).
Although these mechanisms may be important for
rSs-IR/alum-induced protection in the S. stercora-
lis-mouse experimental model with implanted
diﬀusion chambers, it seems plausible that such
mechanisms may not be suﬃcient to prevent the
establishment of patent infections within the small
intestine, and more thorough studies are needed.
Heat shock protein 60 (HSP60) from the rodent
parasite Strongyloides ratti is a naturally immuno-
genic antigen during infection in C57BL/6 mice
that has been shown to be recognized by IgM and
to stimulate proliferative responses in spleen and
mesenteric lymph node (mLN) cells (Ben Nouir
et al. 2012). rSr-HSP60 expressed in E. coli was
emulsiﬁed with complete Freund’s adjuvant (CFA;
TH1-biased), formulated with alum, or used
without adjuvant, and injected i.p. twice at 100 µg
doses. Immunization with rSr-HSP60/CFA, and
interestingly, rSr-HSP60 alone induced a skewed
TH1 response characterized by signiﬁcant IgM,
IgG1, IgG2b/c, and IFN-γ, without IL-13 or sign-
iﬁcant proliferative splenocyte responses (Table 2).
rSr-HSP60 alone was also found to increase IFN-γ
production in DO11·10 mouse splenocytes in vitro
stimulated with cognate ovalbumin peptide. Not
only did either vaccine fail to protect against challenge
infection, but also immunization with rSr-HSP60/
CFA or rSr-HSP60 alone actually slightly increased
susceptibility. Conversely, although immunization
with rSr-HSP60/alum resulted in similar IgM,
IgG1 and IgG2b/c responses compared with rSr-
HSP60/CFA and rSr-HSP60 alone, signiﬁcant prolif-
eration and production of IL-13 without IFN-γ in
splenocytes was observed after rSr-HSP60 stimula-
tion (Table 2). Immunization with rSr-HSP60/alum
resulted in >50% protection against S. ratti challenge
infection (Table 2) (Ben Nouir et al. 2012). IgE
responses were not evaluated, but given the associ-
ation between IL-13 and protection, it seems plausible
that IgE was involved. These ﬁndings clearly indicate
that a TH2 adjuvant such as alum can overrule an anti-
gen’s intrinsic induction of TH1 and provide signiﬁ-
cant protection against a STH infection.
Trichostrongyloids (family Trichostrongylidae) of
livestock
Haemonchus contortus. Haemonchus contortus is a
worldwide trichostrongyloid of small ruminants,
mostly sheep and goats, with a life cycle similar to
hookworms except that L3 attach to the abomasal
mucosa in the ruminant stomach (abomasum) to
feed on blood (Zajac, 2006) (Table 1). Targets of
subunit vaccines for H. contortus have focused pri-
marily on three diﬀerent integral membrane protease
complexes located within the worm’s intestine, H11
aminopeptidase, galactose-containing glycoprotein
(H-gal-GP) and Thiol Sepharose-Binding Protein
(TSBP). In all cases, vaccine-induced immunity is
believed to be due to blocking/neutralizing anti-
bodies. Although high levels of protection have not
yet been achieved with any recombinant subunit
vaccine against haemonchosis, various technical
factors are likely accountable and further studies
are needed.
An adultH. contortus protein extract enriched and
sub-fractionated for the H11 aminopeptidase
complex resulted in an average 71% lowerH. contor-
tus FECs and worm burdens in Merino sheep com-
pared with adjuvant control (Munn et al. 1993). An
H11 aminopeptidase component was cloned and
expressed in the baculovirus-insect cell expression
system (Reszka et al. 2007). Recombinant H11 ami-
nopeptidase-expressing baculovirus-infected insect
cell extracts (bac-rHc-H11) – used instead of puriﬁed
protein due to anticipated immunostimulatory eﬀects
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of insect cell extracts – were injected twice i.m. in
estimated 300 µg doses into Merino sheep. Serum
antibody responses (no mention of classes) were
monitored throughout infection and responses
were higher than bacWT for bac-rHc-H11 after
immunization, although the diﬀerence was not
great (OD of ∼2·25 for bac-rHc-H11 with a back-
ground OD of ∼1·0 for bacWT; responses were
low despite lack of serum dilution). Sheep immu-
nized with bac-rHc-H11 had a signiﬁcant 30%
lower H. contortus worm burdens compared with
bacWT control (Table 2) (Reszka et al. 2007).
Although this study indicated signiﬁcant vaccine
eﬃcacy of bac-rHc-H11 against H. contortus chal-
lenge in sheep, adjuvanted, puriﬁed recombinant
protein, as well as other aminopeptidase components
of the H11 complex, may provide greater protection,
and further investigation is warranted.
H-gal-GP is a detergent-soluble, heavily aspartyl
and metalloproteolytic complex containing 12
diﬀerent proteins, mostly pepsins, metalloproteases
and cysteine protease-like enzymes, as well as a cyst-
eine protease inhibitor and thrombosponin, that
when adjuvanted with CFA provided immunized
Suﬀolk–Greyface cross lambs 72% lower H. contor-
tus worm burdens and 93% lower FECs compared
with CFA alone (Smith et al. 1994; Longbottom
et al. 1997; Redmond et al. 1997; Smith et al.
1999; Skuce et al. 2001). SDS–PAGE separation of
H-gal-GP determined that the isolated, individual
components adjuvanted with CFA are much less
protective alone (Smith and Smith, 1996).
Moreover, reduced and urea-denatured H-gal-GP
and the most protective metalloprotease compo-
nents, as well as their recombinant forms in E. coli,
all adjuvanted with Quil-A, eliminated signiﬁcant
protection against H. contortus, while native H-gal-
GP/Quil-A still resulted in protection similar to
the previous studies (Table 2) (Smith et al. 2003).
These ﬁndings demonstrate that vaccine-induced
protection with H-gal-GP, whether adjuvanted
with CFA or Quil-A, most likely requires a
complex combination of conformational epitopes
provided only by the complex, which has been a
major challenge for its application as a recombinant
subunit vaccine for haemonchosis. The use of
random peptide phage-display libraries has been
suggested as a potential method to identify peptide
sequences in H-gal-GP that potentially mimic the
antigenic epitopes (Ellis et al. 2012).
TSBP is another intestinal, membrane-bound
glycoprotein complex exposed to the luminal surface,
and is enriched with cysteine proteases (Knox et al.
1999), drawing parallels with the partially protective
A. caninum intestinal cysteine protease reported by
Loukas et al. (2004). Suﬀolk–Greyface cross-lambs
injected three times i.m. with TSBP formulated
with CFA, IFA, or Quil-A at 200 µg doses had 95,
54 and 82% lowerH. contortus FECs, and 52, 43 and
45% lower adult worm burdens, respectively, com-
pared with adjuvant controls (reduction in adult
worm burdens for TSBP/IFA was not signiﬁcant)
(Knox et al. 1999). The TSBP intestinal membrane
complex was therefore determined as a highly pro-
tective immunogen when formulated with either
CFA or Quil-A, but surprisingly, protection was
lesser with IFA, a classic TH2 adjuvant.
Immunoscreening of an H. contortus adult, gut-
derived cDNA library with TSBP antisera recog-
nized three Cathepsin-B-like cysteine proteases
(hmcp-1, 4 and 6), and hmcp-1, 4 and 6 were immu-
nolocalized to the gut microvillar surface and found
to be exclusively expressed during blood-feeding
(Skuce et al. 1999). Consistently, TSBP further frac-
tionated for cysteine proteases, formulated with
Quil-A, and injected i.m. resulted in similar levels
of protection compared with the unfractionated
TSBP complex with ∼30% lower H. contortus
worm burdens in trial 1 and ∼46% lower in trial 2,
even with only 3 µg doses per injection of the
former and 100 µg for the latter, and the non-cyst-
eine protease TSBP fraction failed to protect
(Redmond and Knox, 2004). Also, although the
TSBP cysteine protease fraction resulted in slightly
higher numbers of abomasal eosinophils and mast
cells, as well as serum IgE and IgA, but not serum
IgG endpoint titre, compared with unfractionated
TSBP and the non-cysteine protease TSBP fraction,
only serum IgG titre slightly correlated with protec-
tion between individual lambs within the group. For
the TSBP cysteine protease fraction, not only did
total serum IgG titre slightly negatively correlate
with FECs, but also an equal balance between
IgG1 and IgG2 subclasses appeared to be most pro-
tective, though this conclusion did not hold up in a
second trial. Importantly, although recombinant,
E. coli-expressed, trivalent hmcp-1, 4 and 6
expressed as GST-fusions in E. coli cell extracts
(∼80–90% pure proteins), formulated with Quil-A,
and injected three times i.m. at 100 µg doses failed
to lower H. contortus FECs in immunized lambs
compared with Quil-A alone, adult worm burdens
were 38% lower and along with the cysteine protease
fraction and unfractionated TSBP, female worm size
was lower (Table 2). A couple possible explanations
for the lack of reduced FECs for recombinant hmcp-
1, 4 and 6/Quil-A might be immunization with
unpuriﬁed E. coli cell extracts and/or expression as
GST-fusions, of which the GST tag was shown to
account for nearly 80% of the total serum IgG
response in immunized lambs (Redmond and
Knox, 2004). Another possible explanation for the
observed reductions in worm burdens but not
FECs might be due to the fewer number of worms
having elevated fecundities (eggs/adult female),
which could be a possible compensation. Either
way, these ﬁndings clearly indicate that the intestinal
TSBP cysteine proteases are partially protective
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hidden antigens against haemonchosis and hmcp-1,
4 and 6 are candidate immunogens for a recombinant
subunit vaccine. However, although there appears to
be some trend between protection and serum IgG
responses, lack of signiﬁcant immune correlates
indicates the need for further studies of the intestinal
TSBP cysteine proteases, as well as optimization in
diﬀerent recombinant expression systems, which
should also be extended to the H11 aminopeptidase
and H-gal-GP complexes.
In a separate study, another thiol-binding fraction
of H. contortus adult ES enriched with cysteine and
metalloprotease activity was formulated with
Alhydrogel and immunized three times s.c. at 15
µg doses into Zwart-Bles lambs (Bakker et al.
2004). The thiol-binding fraction of ES induced ele-
vated ES-speciﬁc serum IgG, IgA and IgE, but did
not signiﬁcantly elevate mucosal antibody and lym-
phoproliferative responses. These immunizations
resulted in an average 52 and 50% lowerH. contortus
FECs and adult worm burdens, respectively, com-
pared with Alhydrogel alone, but these results were
not signiﬁcant. Although the lower FECs and
adult worm burdens were not statistically signiﬁ-
cant, fecundity was signiﬁcantly reduced for the
thiol-binding fraction, while not for the unbound
fraction or, surprisingly, total ES, injected at 60
and 75 µg doses, respectively, and all formulated
with Alhydrogel. It was speculated that the choice
of adjuvant, although good for thiol-binding frac-
tions, might not have been good for total ES pro-
ducts and thus led to the poor vaccine eﬃcacy
observed (Bakker et al. 2004). There are no pub-
lished data on the vaccine eﬃcacy of recombinant
‘ES-thiol’ proteins against haemonchosis.
To date, the combination of native H11 and H-
gal-GP gut membrane complexes are the most pro-
tective antigen cocktail against haemonchosis. As
mentioned above, the commercialized H. contortus
vaccine Barbervax includes these native complexes
and is highly eﬀective at reducing worm burdens
and egg counts below troublesome levels. A major
issue though is that a protective memory response
is not induced in vaccinated lambs during challenge
infection, so repeated immunizations are required. It
is not yet clear why a protective memory response
fails to be induced during challenge infection, but
it might be due to the complexes containing exclu-
sively hidden antigens.
Ostertagia ostertagi. Ostertagia ostertagi is a major
trichostrongyloid of cattle that infects the abomasal
mucosa feeding on mucus and mucosal tissue, but
unlike H. contortus, is not an obligate blood feeder
(Table 1). These diﬀerences in feeding habit likely
reﬂect the contrasting data found in a vaccine
eﬃcacy study that included the H-gal-GP fraction,
already detailed above and O-gal-GP fraction, both
formulated with Quil-A, against haemonchosis and
ostertagiasis, respectively (Smith et al. 2000).
While H-gal-GP/Quil-A was again found to be
highly protective against haemonchosis at 100 µg
doses in Suﬀolk–Greyface cross-lambs, immuniza-
tion of MontBéliard calves with O-gal-GP/Quil-A
at 200 µg doses failed to provide consistent protec-
tion against ostertagiasis. Quite amazingly though,
immunization of O-gal-GP/Quil-A into lambs
cross-protected against H. contortus with 81–97%
and 57–84% lower FECs and worm burdens,
respectively, compared with Quil-A alone. Thus,
without suﬃcient blood ingestion by O. ostertagi,
host antibodies are most likely incapable of binding
to and blocking/neutralizing O-gal-GP within the
intestine unlike for H. contortus, indicating that
diﬀerences in feeding habits can yield very contrast-
ing results with the same vaccine (Smith et al. 2000).
These data also support the notion that blocking/
neutralizing antibodies may be a good strategy for
vaccine-induced protection against blood-feeding
STHs.
An O. ostertagi adult ES-thiol fraction enriched
with cysteine protease activity, but with the most
abundant antigens being activation-associated
secreted proteins 1 (Oo-ASP-1) and 2 (Oo-ASP-2),
as well as (separately) a membrane-bound thiol sub-
fraction similar to TSBP above, were formulated
with Quil-A and immunized three times i.m. at
100 µg doses into MontBéliard calves (Geldhof
et al. 2002, 2003). Interestingly, the membrane-
bound thiol subfraction, which, considering its
homology to TSBP, is most likely intestinal, failed
to protect against O. ostertagi challenge, consistent
with the contrasting results with H-gal-GP and O-
gal-GP mentioned above. However, immunization
with the ES-thiol fraction resulted in an average
60% lower FECs, 18% lower worm burdens
(though not signiﬁcant) and signiﬁcantly smaller
worms compared with Quil-A alone. Protection
was correlated with the levels of IgA, IgG1 and
IgG2 in the abomasal mucus, and the numbers of
inﬁltrated eosinophils and mast cells within the abo-
masal mucosa were also slightly correlated with pro-
tection (Geldhof et al. 2002). In a follow up study
(Geldhof et al. 2004), the same ES-thiol fraction
was formulated with either Quil-A or Alhydrogel,
and ES-thiol/Quil-A again resulted in similar
levels of protection, while ES-thiol/Alhydrogel
failed to protect. ES-thiol/Quil-A resulted in ele-
vated IgA, IgG1 and IgG2 levels in the abomasal
mucus, and elevated numbers of eosinophils, mast
cells and ‘global leucocytes’ in the abomasal
mucosa compared with ES-thiol/Alhydrogel.
These ﬁndings indicated that Quil-A induces stron-
ger mucosal antibody and cellular immune responses
to ES-thiol compared with Alhydrogel, which likely
accounts for the superior protection (Geldhof et al.
2004). Taken together, the data suggest that for
blood-feeding STHs, blocking/neutralizing serum
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antibody responses may be more important whereas
for non-blood feeding STHs, it might be mucosal
antibody and cellular immune responses that are
more important.
It was later shown that immunization of cattle
with three diﬀerent subfractions of ES-thiol (ASP-
enriched, cysteine protease-enriched and the
remaining non-cysteine protease-enriched or ‘rest’
subfraction) all resulted in even lower O. ostertagi
FECs compared with ES-thiol (Meyvis et al.
2007). Thus, proteins within all three ES-thiol sub-
fractions have protective capacity against ostertagia-
sis. Unfortunately, data for recombinant (r)Oo-
ASP-1 alone, a dominant component in ES-thiol
subfractionation, are not as promising. rOo-ASP-1
was expressed in baculovirus-insect cell expression
system, the cell extract was formulated with Quil-
A and injected three times i.m. at 100 µg doses into
cattle, and no diﬀerences in O. ostertagi FECs or
worm burdens were observed (Table 2) (Geldhof
et al. 2008). Serum from rOo-ASP-1/Quil-A resulted
in much weaker general antibody responses to a native
Oo-ASP-1/2-enriched fraction compared with serum
from cattle immunized with the native Oo-ASP-1/2-
enriched fraction (ODs of∼0·3 and∼2·1, respectively)
(Table 2). It was proposed that rOo-ASP-1 was
incorrectly folded or lacked the protective post-
translational modiﬁcations, or that rOo-ASP-1
alone may be insuﬃcient for protection possibly
requiring the addition of rOo-ASP-2 (Geldhof
et al. 2008). However, there was no mention of the
possibility that puriﬁcation of rOo-ASP-1 from the
crude insect cell extract may improve vaccine
eﬃcacy, similar to that mentioned above for bac-
rHc-H11.
Native O. ostertagi polyprotein allergen (Oo-PA)
formulated with Quil-A resulted in ∼60% lower O.
ostertagi FECs with protection correlated with
mucosal IgG1 and IgG2 responses, while as with
rOo-ASP-1, recombinant protein (this time made
in E. coli) completely failed to protect (Table 2)
(Vercauteren et al. 2004). Thus, although recombin-
ant forms of protective O. ostertagi antigens have
failed to protect cattle from challenge infections,
optimization of and/or use of alternative expression
systems and/or optimized puriﬁcation are warranted
in order to conclusively determine their vaccine
eﬃcacy.
Teladorsagia circumcincta. Teladorsagia circum-
cincta is another abomasal mucus dweller very
similar to O. ostertagi, but mostly infects sheep
(Table 1) (Zajac, 2006). Eight diﬀerent antigens
either, (1) naturally immunodominant for IgA
[cathepsin F-1 (Tci-CF-1); astacin-like metallopro-
teinase-1 (Tci-MEP-1); 20 kDa protein of
unknown function (Tci-ES20); and Tci-ASP-1];
(2) homologous to protective antigens from other
strongylids (Tci-SAA-1); or (3) potential
immunomodulatory proteins [macrophage migra-
tion inhibitory factor-1 (Tci-MIF-1); calcium-
dependent apyrase-1 (Tci-APY-1); and transform-
ing growth factor β homologue (Tci-TGH)], were
evaluated for eﬃcacy in a single, recombinant multi-
valent vaccine. Recombinant proteins were either
expressed in E. coli (rTci-MEP-1; rTci-ASP-1;
rTci-SAA-1; rTci-MIF-1; rTci-APY-1; and rTci-
TGH) or P. pastoris (rTci-CF-1 and rTci-ES20),
formulated with Quil-A, and injected three times
s.c. at 50 µg doses each into Texel cross-bred
lambs. Immunization resulted in elevated serum
and abomasal mucosal IgG and IgA responses for
nearly all recombinant immunogens, and 70%
lower T. circumcincta FECs and 55% lower worm
burdens compared with Quil-A alone (Table 2)
(Nisbet et al. 2013). Thus, this study provided
proof of concept that recombinant subunit vaccines
can work against trichostrongyloids of livestock.
However, whether individual components of the
recombinant vaccine cocktail can protect against tel-
adorsagiasis, or whether speciﬁc combinations are
required has not been resolved.
RECOMBINANT SUBUNIT VACCINES FOR
ASCARIDS
Ascarids (Nematoda clade III, family Ascarididae)
are serious parasites of humans (Ascaris lumbri-
coides), pigs (Ascaris suum), dogs (Toxocara canis)
and cats (Toxocara cati) (Table 1). Species of the
Baylisascaris genus are also important parasites of
wild animals such as giant pandas (Baylisascaris
schroederi) and raccoons (Baylisascaris procyonis),
of which the latter can cause lethal zoonoses. A. lum-
bricoides, the human giant roundworm (can be up to
50 cm in length), infects over 800 million human
beings, making it the most common of the human
STHs (Pullan et al. 2014). Embryonated ascarid
eggs, which can persist in the soil for over 10 years,
are ingested and hatch within the small intestine,
where the infectious larvae burrow into the intestinal
mucosa entering the bloodstream, and then pass
through the liver and heart ultimately breaking free
in the pulmonary alveoli where the larvae undergo
maturation. Similar to N. americanus, larvae
migrate up the bronchial tree into the throat, and
are then swallowed eventually reaching the small
intestine once again where they develop into adult
worms. Adult females can produce over 200 000
eggs per day, and these worms can live within the
small intestine for years (Crompton, 2001).
Infection by A. lumbricoides (and A. suum) is rela-
tively asymptomatic as this nematode consumes
luminal contents rather than host tissue, yet stunts
physical and cognitive development in children
due to signiﬁcant malnutrition (Stephenson et al.
2000). On the other hand, larval migration can lead
to various pulmonary pathologies, and heavy
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patent infections can cause life threatening gut
obstructions, and obstructions to biliary and pancre-
atic ducts due to occasional upstream migration.
Baylisascaris procyonis infection is particularly and
highly dangerous if eggs are ingested by humans
due to the potential for larvae to migrate to the
brain. Also, severe symptoms in young dogs and
cats result from infection by T. canis and T. cati,
respectively, and if humans are infected by them
syndromes known as visceral and ocular larva
migrans can develop where larvae migrate to the
heart, brain or eye, of which the former can be
fatal. Thus, preventing infections by ascarid para-
sites is critical (Crompton, 2001).
Currently there are no published results for
recombinant subunit vaccines against A. lumbri-
coides, while several studies have been published
for A. suum and B. schroederi. Given the recent
common ancestries between these ascarid species
and A. lumbricoides, such studies are highly relevant
to this most prevalent human STH.
Ascaris suum
Intranasal immunization with cholera toxin B (CTB)
subunit. Ascaris suum 14 and 16-kDa proteins
(As14 and As16), as well as As24 and As37 men-
tioned below, are conserved in clade III helminths,
and were suspected to be highly antigenic as they
were determined to be abundantly expressed on
the surface of the infective L3 stage (Kasuga-Aoki
et al. 2001) and are present in ES products. Both
As14 and As16 are homologous to Ac-16 mentioned
above (Fujiwara et al. 2007).
rAs14 was expressed in E. coli, conjugated to CTB
subunit, an adjuvant that enhances mucosal and
systemic immune responses, and immunized i.n.
into BALB/c mice at a primary dose of 50 µg with
two boosters of 30 and 10 µg (Tsuji et al. 2001).
Mice immunized with rAs14-CTB had signiﬁcant
mucosal IgA and serum IgG (with IgG1 the
highest) and IgE responses, and resulted in 60%
lower larval A. suum worm burdens in the lungs
compared with both CTB and rAs14 alone
(Table 2) (Tsuji et al. 2001).
rAs16 was also expressed in E. coli and conjugated
to CTB, and was immunized three times i.n. into
BALB/c mice with a primary dose of 25 µg and
two boosters of 15 and 10 µg in one study (Tsuji
et al. 2003) and into cross-bred Landrace ×
Whitelarge ×Duroc piglets at 300 µg in another
study (Tsuji et al. 2004). In the former study, mice
immunized with rAs16-CTB had signiﬁcant serum
IgG (with equal contributions from IgG1, IgG2a
and IgG3) and IgE responses, but an insigniﬁcant
mucosal IgA response, and highly elevated splenic
rAs16-stimulated IFN-γ and IL-2, as well as signiﬁ-
cant IL-10, but not IL-4 (Table 2) (Tsuji et al.
2003). Somewhat diﬀerently in the latter study,
piglets immunized with rAs16-CTB had signiﬁcant
mucosal IgA and serum IgG (with IgG1 the
highest) (IgE responses were not evaluated), and
was also shown to stimulate elevated IFN-γ, IL-4
and IL-10 from PBMCs (Table 2) (Tsuji et al.
2004). IL-4 and IL-10 were more highly elevated
than IFN-γ in the piglets (Table 2). Both mice and
piglets immunized with rAs16-CTB, similar to
rAs14-CTB above, had 60% lower larval worm
burdens in the lungs compared with both CTB
and rAs16 alone (Table 2) (Tsuji et al. 2003, 2004).
Thus, both rAs14-CTB and rAs16-CTB induced
protection against A. suum larval colonization of the
lung in association with mixed TH1/TH2 mucosal
and/or systemic responses, of which such protection
was completely dependent upon CTB conjugation.
Also, anti-rAs16-CTB mouse and piglet serum loca-
lized As16 to the worm hypodermis and intestine
(Tsuji et al. 2003, 2004) and inhibited moulting of
A. suum L3 in vitro (Tsuji et al. 2004). It was specu-
lated that the mechanism of rAs16-CTB-induced
immunity involves induction of antibodies that
block As16, resulting in moulting defects.
Parenteral immunization. rAs24 was expressed in
E. coli, formulated with CFA, and injected three
times s.c. at 50 µg doses into BALB/c mice (Islam
et al. 2005a). Immunization of mice with rAs24/
CFA resulted in highly signiﬁcant serum IgG1,
IgG2a and IgG2b responses, signiﬁcant rAs24-sti-
mulated splenic IFN-γ and IL-10 (but not IL-4)
responses, and a signiﬁcant 58% less larvae recovered
from the lungs compared with CFA alone (Table 2).
This study clearly indicated an association between
rAs24/CFA-induced protection and a mixed TH1/
TH2-type immune response. The ﬁnding that anti-
rAs24 serum IgG obtained from immunized mice
inhibited the L3 to L4 moult by 26% in vitro sug-
gests a role for serum IgG in rAs24/CFA-induced
protection. As24 was also strongly localized to the
hypodermis, supporting a potential role in the
moulting process (Islam et al. 2005a).
As37, in addition to being abundantly expressed
on the surface of A. suum L3, is immunodominant
and recognized by serum obtained from previously
infected, fenbendazole-treated pigs (Kasuga-Aoki
et al. 2001). TheAs37 amino acid sequence harbours
multiple Ig domains and has similarity to proteins of
the Ig superfamily, as well as nematode twitchin and
mammalian skeletal muscle titin. Native As37 was
localized in the muscle and hypodermis, as well as
in the ovaries, eggs and lateral and dorsal chords of
A. suum adult females, indicating a rather ubiquitous
expression pattern. Sera from rabbits, mice and pigs
infected with A. suum embryonated eggs reacted
with E. coli-expressed rAs37, supporting natural
immunogenicity of As37. BALB/c mice were
injected with rAs37/CFA three times s.c. (doses
not reported), and, although immunized mice had
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signiﬁcant serum IgG responses, signiﬁcant reduc-
tion in the number of larvae in the lungs was not
observed (Table 2). It was proposed that alternative
expression systems and/or routes of immunization
need to be tested in order to determine whether or
not rAs37 has protective vaccine eﬃcacy (Tsuji
et al. 2002).
Ascaris suum inorganic pyrophosphatase (As-
PPase) is conserved in ascarids and was shown to
play a role in larval development and moulting,
but was also shown to be expressed throughout the
life cycle, and to localize in the hypodermis and
adult reproductive tissues (Islam et al. 2003).
Knockdown of As-PPase by RNA interference
(RNAi) inhibited moulting of L3 to L4 in vitro by
31%, with only around 56% reduction in As-PPase
protein levels (Islam et al. 2005b). rAs-PPase was
expressed in E. coli, formulated with TiterMax
Gold adjuvant, and injected three times s.c. at 50
µg doses into BALB/c mice. Immunization with
rAs-PPase/TiterMax resulted in signiﬁcant serum
IgG responses (predominantly IgG1), signiﬁcant
production of splenic IL-10 (but not IFN-γ, IL-2
or IL-4) after rAs-PPase stimulation, and over 70%
less A. suum larvae in the lungs compared with
TiterMax alone (Table 2). Also, anti-rAs-PPase
serum from immunized mice recognized native As-
PPase, localized it to the hypodermis of lung-stage
larvae, and inhibited L3 to L4 moulting in vitro by
up to 57%. Finally, immunoreactive plasmids from
the Novotope system mapped IgG-binding epitopes
to sites spread across the whole rAs-PPase protein,
including the active site (Islam et al. 2005b).
Although the latter experiment did determine that
epitopes overlap with the active site, the Novotope
system is limited to contiguous epitopes, and it was
not resolved for whether or not protection is
mediated by serum IgG-binding to linear or discon-
tinuous conformational epitopes within the As-
PPase active site. Nonetheless, this study revealed
rAs-PPase/TiterMax Gold as the recombinant
subunit vaccine that provides the greatest protection
against invasive L3 tissue migration to date in mice.
It was speculated that the mechanism of vaccine-
induced immunity involves IgG-binding and block-
ing/neutralizing native As-PPase in the hypodermis,
thus disrupting larval development and moulting,
and hence, eﬃcient migration and development
within the lung (Islam et al. 2005b). Surprisingly,
the protection was clearly associated with IL-10,
an anti-inﬂammatory cytokine (Couper et al. 2008).
Enolase is suspected to be involved in glycolysis,
and knockdown of A. suum enolase (AsEnol) by
RNAi indicated an important role in larval develop-
ment (Chen et al. 2011). AsEnol has been identiﬁed
in ES products, despite the fact that it is missing an
N-terminal signal peptide (Huang et al. 2008), sug-
gesting a function in the host. Chen et al. (2012)
investigated the vaccine eﬃcacy of AsEnol using a
DNA vaccine approach in mice. An AsEnol cDNA
was cloned into the pVEX I expression plasmid,
transfected into Marc-145 cells and expression and
immunogenicity of rAsEnol was veriﬁed by indirect
immunoﬂuorescence assay using pVEX I-AsEnol
serum from mice. pVEX I-AsEnol was immunized
three times i.m. at 100 µg doses into Kunming
mice in the absence of a transfection reagent or adju-
vant. Immunization resulted in signiﬁcant total
serum IgG responses against A. suum crude larval
extract (AsCE), and signiﬁcant splenicAsCE-stimu-
lated IFN-γ, IL-2, IL-4 and IL-10 responses
(Table 2). IFN-γ was much more highly elevated
compared with the other cytokines. Also, immuniza-
tion with pVEX I-AsEnol resulted in signiﬁcant pro-
liferative responses in splenocytes stimulated with
AsCE (Table 2), indicating an established memory
TH cell response. Finally, pVEX I-AsEnol resulted
in an average 44% less larvae recovered in either
the liver or lung compared with pVEX I alone
(Table 2), thus indicating signiﬁcant eﬃcacy of this
DNA vaccine, characterized by a TH1-skewed cyto-
kine proﬁle with minor TH2 contributions (Chen
et al. 2012).
Baylisascaris schroederi
Baylisascaris schroederi antigens (Ag) 1, 2 and 3 are
homologous to As14, As16 and As37 mentioned
above, respectively. Hence, their eﬃcacies as
recombinant subunit vaccines against experimental
B. schroederi infection in mice were evaluated in
order to develop alternative control measures for
this critical STH of the endangered giant panda, of
which the prevalence of infection is between 70
and 100% (Wang et al. 2008; He et al. 2009, 2012).
rBs-Ag1 (He et al. 2012), rBs-Ag2 (He et al. 2009)
and rBs-Ag3 (Wang et al. 2008) were expressed in
E. coli, formulated with CFA, and injected three
times i.p. at 30 µg doses into BALB/c mice. Mice
immunized with all three vaccines had signiﬁcant
serum IgG responses and had a signiﬁcant 60% less
B. schroederi larvae recovered in the lungs compared
with CFA alone (Table 2) (Wang et al. 2008; He
et al. 2009, 2012). These studies were in concordance
with the vaccine studies for rAs14 and rAs16, but
diﬀerent from the results obtained with rAs37,
which may reﬂect the diﬀerences in route of immun-
ization (s.c. vs i.p.) or other technical/biological
factors. Regardless, these three recombinant immu-
nogens serve as possible candidates for a vaccine to
control baylisascariasis in giant pandas.
The eﬃcacy of the B. schroederi homologue of As-
PPase mentioned above (Bs-PYP-1) as a recombin-
ant subunit vaccine against experimental infection
in mice was also investigated (Xie et al. 2013). rBs-
PYP-1 was expressed in E. coli, formulated with
CFA, and injected three times s.c. at 50 µg doses
into BALB/c mice in two separate trials. In both
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trials, immunization with rBs-PYP-1/CFA resulted
in signiﬁcant serum IgG responses (with IgG1
much greater than IgG2a), signiﬁcant production
of rBs-PYP-1-stimulated splenic IL-4 and IL-10
(with IL-10 much greater than IL-4), without pro-
duction of IFN-γ or IL-2, and a signiﬁcant 70%
less B. schroederi larvae recovered in the lungs
(Table 2). Other than the signiﬁcant production of
IL-4, these results were in concordance with the
ﬁndings for the rAs-PPase homologue mentioned
above, again demonstrating a unique role for IL-10
in vaccine-induced immunity to these ascarids.
Also similar toAs-PPase, native Bs-PYP-1 was loca-
lized to the hypodermis and reproductive tissues
with anti-rBs-PYP-1 serum, but also localized to
the muscle tissues and intestine, and thus, was
more ubiquitously expressed (Xie et al. 2013). The
inorganic pyrophosphatase conserved in ascarids
therefore remains as the most promising vaccine can-
didate to date for these critical parasites of animals
and humans.
It must be mentioned that all of these previous
studies of recombinant subunit vaccines in ascarids
have focused on target antigens abundantly expressed
and/or present on the surface of infective L3.
Although there is no direct evidence for pre-existing
serum IgE against ascarid L3 antigens resulting in
allergic reactions when immunized into previously
infected humans or animals, the studies in hookworms
present an alarming issue. Studies must be conducted
to determine if these candidate immunogens will pass
safety testing in humans and veterinary animals,
because if not, future developments in ascarids
should no longer focus on L3 antigens.
RECOMBINANT SUBUNIT VACCINES FOR
TRICHURIDS
Trichurids (Trichuris spp.; whipworms; Nematoda
clade I) are critical parasites of livestock, dogs, cats
and humans, and infect various rodents. Trichuris
trichiura (Table 1) is the only well-known human
trichurid, infecting almost 500 million people
(Pullan et al. 2014). Trichuriasis can be character-
ized by painful passage of the stool and rectal pro-
lapse with heavy infections, and in children, can
lead to severe anaemia, stunted growth and cognitive
development. Trichurids begin their life cycle when
embryonated eggs are ingested by the host. Once the
eggs reach the duodenum, they hatch. Larvae either
mature in the small intestine, or travel to the cecum
of the large intestine for maturation, feeding on
tissue ﬂuids, the mucosal epithelium, and possibly
blood, but evidence for the latter remains inconclu-
sive. Adult trichurids anteriorly ﬁxed within the
intestinal mucosa mate, and each female lays
between 3000 and 20 000 unembryonated eggs per
day in the cecum and ascending colon that are
passed with the feces, embryonating after several
weeks and continuing the next cycle once ingested.
The lifespan of T. trichiura is about 1 year (Bundy
and Cooper, 1989).
Although there are no published studies for
recombinant subunit vaccines for any trichurid, vac-
cination of mice with adult Trichuris muris ES pro-
ducts resulted in almost complete protection
against T. muris egg challenge, in association with a
classical TH2 response (Dixon et al. 2010). Also, a
few studies have obtained promising results for the
zoonotic parasite Trichinella spiralis (Table 1),
which, like trichurids, is also found in clade I
Nematoda. Although T. spiralis has a considerably
diﬀerent life cycle than trichurids – transmission to
humans occurring from ingestion of larvae-contami-
nated meat, followed by larval maturation to adults
that deposit eggs within the small intestine that
hatch, and then the larvae penetrate the intestinal
mucosa and subsequently migrate to muscle tissue
for maturation into cysts – many antigens are likely
to contain high amino acid identities and to poten-
tially have similar functions.
Three related studies in mice determined the
vaccine eﬃcacy of the immunodominant and/or
immunomodulatory surface and/or ES proteins
Ts87, TsGp43 and paramyosin (TsPmy) delivered
as DNA vaccines in recombinant, attenuated
Salmonella enterica serovar Typhimurium for induc-
tion of mucosal immune responses (Yang et al.
2010b; Pompa-Mera et al. 2011; Wang et al. 2016).
Vaccines were administered three times either
orally or i.n. and elicited signiﬁcant mucosal IgA
and/or serum IgG1/IgG2a as well as elevated TH1
and TH2-associated cytokines (Table 2).
Vaccination resulted in signiﬁcantly less (between
30 and 50%) T. spiralis worm burdens in muscle
tissue compared with control (Table 2). Though
these recombinant subunit, oral vaccines for T. spir-
alis are encouraging for trichurids, the eﬃcacy of
oral vaccination against T. muris in mice was
shown to depend upon host genetics, and less so
for parenteral vaccination (Robinson et al. 1995).
Nonetheless, TsPmy resulted in similar vaccine
eﬃcacy when administered s.c. as an E. coli-
expressed protein-based vaccine formulated with
CFA (Yang et al. 2010a), and thus, appears to be
the most encouraging of the three antigen targets
for potential application to trichurids.
A very recent study (Xu et al. 2017) used a naked
DNA vaccine approach (i.e. no adjuvant or transfec-
tion reagent) to test the vaccine eﬃcacy of a serine
protease (Ts-NBLsp) expressed speciﬁcally in the
newborn larval (NBL) stage, which is the stage
when T. spiralis colonizes the striated muscle tissue
after migrating from the small intestine. A Ts-
NBLsp cDNA was cloned into pcDNA3·1+ and
injected twice i.m. at 60 µg doses into the quadriceps
of Kunming mice, where expression of the recom-
binant Ts-NBLsp protein was conﬁrmed by
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immunoﬂuorescence. Mice immunized with
pcDNA3·1(+)-Ts-NBLsp had elevated serum
IgG1 and IgG2a responses, with the latter higher
than the former, but responses were weak overall
(maximum IgG1 OD450 =∼0·3; maximum IgG2a
OD450 =∼0·55; background =∼0·1; 1 : 50 serum
dilution) (Table 2), consistent with the previous
studies on DNA vaccines mentioned above.
Interestingly, the ratio of CD4+/CD8+ T cells in
peripheral blood was signiﬁcantly lower in both
pcDNA3·1+/Ts-NBLsp and pcDNA3·1+ empty
vector control mice compared with PBS control
mice (i.e. the population of CD4+ T cells were
reduced and/or CD8+ T cells expanded) (Table 2).
Consistent with an expansion of CD8+ T cells in per-
ipheral blood, IFN-γ was also signiﬁcantly elevated in
the peripheral blood for both pcDNA3·1+/Ts-NBLsp
and pcDNA3·1+ empty vector control mice compared
with PBS control mice, and higher (but not signiﬁ-
cant) in pcDNA3·1+/Ts-NBLsp compared with
pcDNA3·1+ (Table 2). On the other hand, IL-10
and IL-4 were signiﬁcantly elevated in the peripheral
blood of only pcDNA3·1+/Ts-NBLspmice (Table 2).
Mice immunized with pcDNA3·1+/Ts-NBLsp had
∼78% less T. spiralis larvae recovered in muscle
tissue (Table 2), and interestingly, pcDNA3·1+
empty vector control mice also had a signiﬁcant 30%
less T. spiralis larvae, compared with PBS control
mice (Xu et al. 2017). These ﬁndings indicated that:
(1) the pcDNA3·1+ vector alone induces a non-
speciﬁc cell-mediated immune response within the
muscle tissue that reduces susceptibility to T. spiralis
larval colonization, and (2) pcDNA3·1+/Ts-NBLsp
is a highly protective DNA vaccine that greatly
reduces NBL colonization of the muscle tissue, in
association with a mixed TH1/TH2-type immune
response. It is also worthmentioning that the apparent
elevation in CD8+ T cells, and association with pro-
tection, makes sense as TH1 eﬀectors are known to
be protective against the T. spiralis NBL stage (but
not TH2 eﬀectors), which becomes an intracellular
pathogen within the muscle tissue. Finally, although
T. spiralis infects its host much diﬀerently, it would
be worthwhile to explore the NBLsp homologue in
trichurids to determine if by targeting this antigen,
similarly high levels of protection can be achieved.
DISCUSSION
These previous studies of recombinant subunit vac-
cines for STHs have reported many possible candi-
dates for further optimization, and some that
progressed to clinical trials. However, collectively
reviewing all of these studies has revealed many diﬀer-
ences in vaccine design and their administration.
Examples include the use of protein or DNA vaccines,
E. coli or eukaryotic expression systems, TH1 or
TH2-biased adjuvants, many diﬀerent routes of
immunization, diﬀerent amounts of immunogen and
the number of injections, among many other incon-
sistencies. Below, we brieﬂy discuss and interpret the
results from these previous studies as a whole in an
attempt to help guide future developments.
Protein or DNA vaccines?
An important diﬀerence between protein and DNA
vaccines, is that the former has been used successfully
in humans since themid-20th century (Plotkin, 2014),
but not a single DNA vaccine has been shown to work
in humans. An advantage of protein vaccines is that
the immunogen (i.e. an extracellular antigen) is pro-
cessed and presented on Class II MHC by profes-
sional APCs, and along with adjuvant, this can
shape intricate TH responses, and clearly the majority
of successes with recombinant subunit vaccines for
STHs have been protein-based. However, with
DNA (and RNA) vaccines the immunogen must be
translated within the host cell cytoplasm, and hence,
can only be presented by Class I MHC. Thus, the
immune response(s) is generally limited to TH1, and
particularly to CD8+ TC cells (Ferraro et al. 2011).
This may explain the weak antibody responses gener-
ated against rAcey-MEP-6 and rAcey-MEP-7 in
golden hamsters using the pcDNA3·1+/Fugene 6
system against A. ceylanicum (Wisniewski et al.
2013, 2016), against rSs-EAT-6 peptide in mice
using the Lambda Uni-zap XR vector/GM-CSF
system against S. stercoralis (Kerepesi et al. 2005),
and against rTs-NBLsp in mice using pcDNA3·1+
alone against T. spiralis. However, DNA vaccines in
mice have proven to be highly eﬃcacious against A.
suum (Chen et al. 2012) and T. spiralis (Yang et al.
2010a; Pompa-Mera et al. 2011; Wang et al. 2016),
with signiﬁcant immunogenicity (albeit relatively
weak for pcDNA3·1+/Ts-NBLsp) and protection
achieved. Moreover, though DNA vaccines against
A. suum and T. spiralis resulted in signiﬁcant TH1
responses, as would be expected, there were contribu-
tions from TH2 cytokines as well. These studies dem-
onstrate that the immune responses to DNA vaccines
against STHs are likely to be more complex than that
appreciated, and this type of recombinant subunit
vaccine may prove to be broadly applicable in the
future with more thorough studies. However, it will
be important for future studies to address the safety
concerns of host gene modiﬁcation and uncontrollable
gene expression beforeDNAvaccines can be a realistic
STH control measure.
Escherichia coli or eukaryotic expression systems for
protein-based vaccines?
Escherichia coli would be the most cost eﬀective
system for expressing recombinant proteins for
STH vaccines, which is important given that the
target populations are people living in poverty.
However, it is widely known that recombinant
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expression of eukaryotic proteins in E. coli often
results in the proteins being expressed in insoluble
inclusion bodies. Inclusion bodies must then be
solubilized with harsh detergents, and often
reduced, thus causing denaturation with the major
challenge of refolding into native conﬁrmation.
Also, even in the rare event that the protein does
express in E. coli in the soluble fraction, still,
folding is often incorrect, and eukaryotic post-trans-
lational modiﬁcations – common on secreted pro-
teins – are deﬁcient. These deﬁciencies of E. coli
are signiﬁcant for vaccine development given that
adequate immunogenicity often requires discontinu-
ous conformational B cell epitopes (Andersen et al.
2006). Hence, eukaryotic expression systems such
as yeast (P. pastoris or K. lactis) and baculovirus-
insect cells are likely to be more suitable for produc-
tion of recombinant proteins for vaccines against
STHs. On the other hand, although the majority
of successful recombinant subunit vaccines for the
strongylids have been with these eukaryotic expres-
sion systems, with most attempts having failed
with E. coli (especially in the trichostrongyloids),
the major successes in ascarids with E. coli presents
a signiﬁcant incongruence. Could it be that some
immunogens (e.g. those mentioned above for ascar-
ids) induce protection through linear T cell epitopes
independent from B cells, similar to the natural
immune responses (Anthony et al. 2007; Nair and
De’Broski, 2016), while other immunogens (e.g.
many of those mentioned above for stongylids)
require non-linear B cell epitopes? It seems likely
that success in any expression system will vary on a
protein-to-protein basis for any STH, and more
thorough studies of the immunobiology of STH
infections will help to explain the protein-to-
protein variations that have been observed.
What are the best immune correlates of vaccine-induced
protection?
B cells. There have been many immune factors
found to be associated with vaccine-induced protec-
tion against STHs. Serum IgG1, IgG2 and IgE, and
mucosal IgA [i.e. secretory (s)IgA], IgG1 and IgG2
are antibodies often found to be elevated in immunized
animals. IgG1/IgG2 in both serum and mucosa have
been found to be correlated with the level of protec-
tion, and in some cases, so has sIgA. In some cases,
equal balance of IgG1 and IgG2 were found to correl-
ate with the greatest level of protection. As IgG1 is
considered the TH2 subclass, while IgG2 is considered
the TH1 subclass, most relate this equal balance to a
mixed TH1/TH2 response. However, although TH2-
dominated cytokine proﬁles were nearly always asso-
ciated with IgG1-dominated serum antibody, many
of the previous studies report IFN-γ-dominated cyto-
kine proﬁles also with highly elevated IgG1, often
higher than IgG2. So it is unclear if IgG1 is speciﬁc
for TH2 in vaccine-induced immune responses to
STHs, and cytokines must also be evaluated to deter-
mine the type of TH response. Also, in some studies
protection was correlated with IgG1 or balanced
IgG1/IgG2, while in others, sIgA was more
highly correlated. Importantly, although the IgG
class has been ascribed the function of ‘blocking/
neutralizing’ target antigen function for hook-
worms, inhibiting protein activity in vitro,
passive transfer experiments with puriﬁed anti-
bodies have not been performed. Thus, it has not
been conclusively determined if antibodies in
general are suﬃcient for vaccine-induced protec-
tion, and if any one class is suﬃcient. However, it
was shown that passive transfer of serum speciﬁc for
rSs-IR resulted in similar levels of protection against
Ss challenge infection compared with immunized
donor mice (Abraham et al. 2011), thus supporting
the role of antibodies in vaccine-induced protection.
That said, Abraham et al. (2011) speculated that anti-
bodies were not blocking/neutralizing antigen func-
tion per se, but that the protection was via
complement and/or ADCC.
T cells. Antigen recall responses in peripheral
blood, spleens, or mLNs of immunized animals
have found that IFN-γ, IL-4 and IL-13 are frequently
elevated indicating that protection is often associated
with mixed TH1/TH2 responses, consistent with
common elevations of both IgG1 and IgG2. In
some cases, IL-10 was also elevated, and in other
cases, IL-10 dominated the cytokine pool, thus dem-
onstrating that IL-10s role in vaccine-induced
immunity to STHs may be more complicated than
typically appreciated (i.e. it may not be just an anti-
inﬂammatory cytokine). But the levels of all these
cytokines were highly variable between studies. As
with antibodies, it is unclear which, if any, of these
cytokines are necessary for vaccine-induced protec-
tion. In vivo experiments with cytokine knockout
animals or with blocking/neutralizing antibodies will
need to be performed to determine if any of these
cytokines are necessary for protection, and adoptive
transfer experiments should be performed to deter-
mine whether T cells are suﬃcient, or whether anti-
bodies are also required. Furthermore, many more
cytokines should be evaluated in future studies to
more thoroughly characterize the TH responses asso-
ciated with protection. Finally, studies should
compare the levels of cytokines produced by lym-
phocytes in response to antigen stimulation in the
diﬀerent lymph tissues. Although most studies
have found that lymphocytes from immunized
animals proliferate signiﬁcantly in response to
antigen, it would also be worthwhile to compare pro-
liferative responses between diﬀerent lymph tissues.
Innate immune cells. Studies of the trichostrongy-
loids showed nicely that the granulocytes
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eosinophils, basophils and mast cells were elevated
locally within the abomasum, and in some cases cor-
related with the level of protection. Such experi-
ments should be extended to the other STHs to
determine whether these innate immune cells, or
others, such as neutrophils, macrophages, den-
dritic cells and even natural killer cells, are (or are
not) signiﬁcantly elevated within the local tissue,
which could ultimately help to enhance vaccine-
induced protection.
Does adjuvant really matter for parenteral vaccines?
One of the most variable factors among these previ-
ous studies was the choice of adjuvant. Given the
conserved association of TH2-type responses with
immunity to STHs, TH2-biased adjuvants make
sense. However, the paradigmatic natural immune
responses to STHs are clearly not conserved with
the immune responses associated with recombinant
subunit vaccines. Loukas et al. (2004) showed that
whether TH1 or TH2-biased adjuvant was used
with rAc-CP-2 did not signiﬁcantly change the
immunogenicity and protection against A. caninum
challenge infection induced in beagles. And multiple
studies for hookworms used either TH1 or TH2
adjuvants with success, and the associated immune
responses – elevated IgG1/IgG2 – were overall con-
sistent with both classes of adjuvants (although cyto-
kines were never evaluated for TH2 adjuvants, so
they cannot be compared with the cytokine
changes observed for TH1 adjuvants). Also, studies
in ascarids and T. spiralis had much success with
CFA, a heavily TH1-biased adjuvant, with elevated,
and in some cases dominant, TH2 cytokine proﬁles.
It seems reasonable to question if the immunogens
alone can override adjuvant induction of TH1 and/
or TH2, but such experiments were not conducted
to be certain.
On the other hand, studies in the non-hookworm
strongylids found that the choice of adjuvant can
determine the outcome of vaccination. Ben Nouir
et al. (2012) showed that rSr-HSP60, which inher-
ently induces TH1, resulted in an IL-13-dominated
cytokine proﬁle and partial protection when formu-
lated with alum, but with CFA actually increased sus-
ceptibility to S. ratti challenge infection. Conversely,
in the trichostrongyloids, multiple native immuno-
gens lacked signiﬁcant protective eﬀects when formu-
lated with TH2 adjuvants (IFA or Alhydrogel), but
with Quil-A (and CFA) resulted in signiﬁcant pro-
tection (Knox et al. 1999; Geldhof et al. 2004), pos-
sibly suggesting that adjuvant induction of TH1 or a
mixed TH1/TH2 response is necessary for the mech-
anism of vaccine-induced protection, at least in these
trichostrongyloids.
Clearly we are far from understanding the mech-
anism(s) of vaccine-induced protection against
STHs, and it is likely that each STH will be distinct
in one way or another. Thus, the ﬁeld of STH vacci-
nology needs to better bridge with immunobiology
for us to more rationally design better recombinant
subunit vaccines.
Parenteral or oral/intranasal immunization?
Parenteral immunizations have dominated the litera-
ture for the development of STH vaccines.
However, in considering the target populations
that are most aﬄicted by STHs, oral/i.n. vaccines
are likely to be more ideal due to their ease of self-
administration, which would likely allow for a
much wider dispersal, and for their induction of
local, mucosal immune responses. Previous studies
of A. suum and T. spiralis had much success with
oral or i.n. immunizations, and the success in A.
suum with simple conjugation of immunogen to
CTB (CTB subunit) is promising for all STHs.
However, as mentioned above, Robinson et al.
(1995) showed that BALB/c high and C57BL/10
and B10.BR low-responder mice were all protected
against T. muris challenge infection when immu-
nized s.c. withT. muris adult worm extract, with ele-
vated serum IgG1 and IFN-γ and IL-5 cytokine
proﬁles. However, only BALB/c high and C57BL/
10 low-responder mice were protected against
T. muris when immunized orally, while B10.BR
low-responder mice were not protected and had neg-
ligible immune responses. Also, the success of oral/
gut mucosal vaccines in endemic human populations
for other enteric pathogens such as S. enterica
serovar Typhi and Vibrio cholera has been demon-
strated to depend largely on underlying genetics
(Pasetti et al. 2011). Thus, although oral/i.n. vac-
cines may be a hopeful goal for STH vaccines (espe-
cially for humans), the lesser dependence on host
genetics for parenteral vaccines suggests a greater
likelihood of success in clinical trials.
Does immunization regimen matter?
A likely underappreciated factor that is important
for vaccine design is the number of injections and
amount of immunogen per injection. With reduc-
tionist vaccine design (at least in the simplest
terms), the number of injections and amount of
immunogen (as well as route of administration and
form of immunogen) can be optimized in order to
achieve a desired immune response (e.g. suﬃcient
aﬃnity maturation) (Jardine et al. 2016). Nearly all
of the previous studies of recombinant subunit vac-
cines for STHs used three equally dosed injections,
with small rodents (mice and golden hamsters) gen-
erally receiving between 20 and 50 µg doses, and
larger animals (beagles, sheep and cattle) receiving
from 50 to 300 µg doses. No studies have actually
adequately compared diﬀerent numbers of injections
and doses of the same vaccine, but such a study may
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prove worthwhile, especially considering that min-
imizing the number of immunizations (and doses)
required for protection will be critical for the
success of these vaccines in target populations. A
few studies did, however, diﬀer from the standard
of three injections, with signiﬁcant protection
achieved with just two injections (Reszka et al.
2007; Ben Nouir et al. 2012), suggesting that this
may be the minimum number. Regardless, it is
very likely that the dose and frequency of exposure
will vary with antigen and host and will probably
have to be empirically determined for each case.
Should naturally hidden or exposed antigens be targeted?
The mechanisms of vaccine-induced protection
against STHs have not been completely resolved,
only extensively postulated. To use hookworms
and H. contortus as an example, the idea behind tar-
geting STH proteins that are present within STHs’
intestinal lumens is that these proteins are accessible
to antibodies ingested in the hosts’ blood. The anti-
bodies bind to the target proteins, and block/neutral-
ize their activities/functions. These proteins have
been called hidden antigens, as mentioned above,
because naturally they are physically concealed
from the host immune system inside of the blood-
feeding STHs’ bodies. The current deﬁnition of
hidden antigen does not include those antigens that
naturally are physically exposed to the host
immune system (e.g. proteins in ES products) and
immunologically silent for unknown reasons,
which could be distinguished from hidden antigens
by from now on being called immune-silent ES pro-
teins. Now hidden intestinal proteins in STHs that
do not normally ingest blood (see Table 1) may not
be as useful to target, as exempliﬁed by comparing
the eﬃcacy of the same vaccine against H. contortus
and O. ostertagi (Smith et al. 2000). However, as
most non-blood-feeding STHs normally ingest
large amounts of mucus within the GI tract, induc-
tion of high titre of sIgA as well as IgG within the
mucosa might grant these antibodies access to
block/neutralize the hidden intestinal proteins
within these worms. But again, since passive transfer
experiments of puriﬁed antibodies speciﬁc for indi-
vidual immunogens have not been performed, it is
uncertain whether blocking/neutralizing antibodies
are in fact solely responsible for vaccine-induced
protection, even against hookworms andH. contortus.
Targeting hidden intestinal antigens is justiﬁed by
studies in hookworms. Naturally immunodominant
ASP-2 secreted by hookworm infective L3, although
partially protective, resulted in allergic reactions
when immunized into previously infected indivi-
duals due to pre-existing ASP-2-speciﬁc IgE, as
mentioned above. Thus, targeting antigens that are
not naturally immunogenic avoids such risks. But
an important question unaddressed for the hidden
antigen approach is whether or not recall responses
will be suﬃciently induced in memory lymphocytes
in vaccinated individuals if in fact the native antigens
are hidden from the immune system. In the experi-
mental vaccine studies (including with hidden
intestinal antigens), animals were challenged soon
after they were immunized, and thus, acute immune
responses were likely still existent. In order to
answer this important question, it would be worth-
while to at least investigate the lifetime of protection
for such vaccines that target hidden intestinal antigens
in the animal models for experimental vaccination.
On the other hand, what about targeting antigens
exposed on the surface of L4 and/or adult worms
(while also absent from L3), or that are secreted
into the local environment (i.e. proteins in ES pro-
ducts)? In theory, many of these antigens would be
both immunologically accessible and more likely to
induce long-lasting recall responses in immunized
individuals, because they are in fact exposed. And
as long as these antigens are not produced by infect-
ive L3 (most notably in hookworms), natural
immunogenicity in these later stages may not
matter. There would also be the option of using
the exposed antigens to direct the natural immune
mechanisms that exist to expel STHs from the GI
tract. Such an approach may also help to better
bridge the currently largely independently operating
ﬁelds of STH vaccinology and immunobiology.
How valid are the laboratory challenge infection
models?
All of the preclinical vaccine studies above for
human STH infections used various laboratory chal-
lenge infection models. Although there is no way of
conducting preclinical studies directly on humans,
there are likely limitations with these models.
These limitations include the use of model hosts,
STH species other than the target species, laboratory
strain of the target STH species, unnatural infection
and other limitations. With the use of model hosts
such as golden hamsters, mice rats, and beagles,
and laboratory STH species/strains that are genetic-
ally diﬀerent from natural species/strains, it is
unclear if any of the vaccines will translate to
humans, and such studies are warranted. Also, the
use of unnatural infections such as the diﬀusion
chambers for S. stercoralis in mice, or inoculating
mice with ascarids, which are not able to establish
patent infections in the mouse small intestine, add
further limitation for extrapolating to humans.
Furthermore, most of the vaccine trails for each
STH were conducted by only one or two diﬀerent
labs. More technical, laboratory-to-laboratory varia-
tions such as diﬀerent laboratory STH strains,
diﬀerent viability and dose of inocula, diﬀerent
host species or strains and just simply diﬀerent
reagents, equipment and researchers could cause
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extensive variation in results. As the ﬁeld of STH vac-
cinology continues to grow, the reproducibility of the
results obtained for these recombinant subunit vac-
cines will likely be addressed.
How can we better streamline antigen selection?
If blocking/neutralizing antibodies really are the
bases of the protection achieved from the previous
studies on recombinant subunit vaccines for STHs,
then the antigens must have essential/important
functions for infection. With the advent of whole
genome sequencing combined with transcriptomics
and proteomics, we are now capable of ﬁltering out
candidate antigens unlikely to be important for
infection and/or to be present in immunologically
inaccessible sites within the worms through bioinfor-
matics and computational biology. Although a chal-
lenge, we can similarly prioritize for candidate
antigens using the same methods, which will greatly
increase the probability of testing antigens that have
essential/important functions. The genomes have
already been published for many of the most critical
STHs (Table 1), and thus, much of the data needed
for prioritization is already at hand.
Even with genomics-assisted selection of candi-
date antigens for experimental vaccination, import-
ance/essentiality for infection can only be validated
through reverse genetics. RNAi was used success-
fully to validate important functions of multiple
A. suum antigens and subsequent vaccine studies
resulted in comparatively high levels of protection
(Islam et al. 2005a, b, Chen et al. 2011, 2012).
Although RNAi has had variable success so far in
other STHs such as H. contortus (Britton et al.
2012), this tool may still be useful for validation
studies of particular antigens. An alternative
reverse genetics tool for validation studies might be
the CRISPR-Cas9 system for generating single
gene knockouts. But although heritable loss-of-
function mutants have been obtained in C. elegans
using CRISPR-Cas9 (Friedland et al. 2013), no
results have been published in STHs, so the
eﬃcacy of this system for validating important func-
tions of candidate antigens is unknown at this time.
Another possible method to better streamline
antigen selection could be to screen STH antigens
for recognition by putative immune sera collected
from people living in endemic regions that have high
antibody titre and low worm burdens. However, if
these antigens happen to be recognized by IgE in
these humans, it is not likely that they will be useful
as vaccine candidates given the ﬁndings with hook-
worm ASP-2 (Diemert et al. 2012).
Are pan-anthelmintic vaccines possible?
The idea of a single, multivalent, pan-anthelmintic
vaccine to control the three major human STHs
(hookworms, A. lumbricoides and T. trichiura) has
been proposed (Zhan et al. 2014). By including one
or two recombinant protein immunogens for each
STH, it is believed that all can be immunologically
controlled simultaneously (Zhan et al. 2014).
However, though such a vaccine would be ideal,
the diﬀerent locations that these STHs occupy
within the GI tract and/or diﬀerent feeding habits
(Table 1) may present an enormous obstacle for a
single vaccine. As mentioned above, adjuvants that
worked well against one STH completely failed
against another, and targeting hidden intestinal anti-
gens in hookworms may work diﬀerently (or not at
all) inA. lumbricoides andT. trichiura. And in combin-
ationwith these three diﬀerent STHs being phylogen-
etically distant relatives (i.e. fromNematoda clades V,
III and I, respectively), the immunobiological factors
involved in vaccine-induced protection against each
of them is likely to be considerably diﬀerent. On the
other hand, pan-strongylid, pan-ascarid and pan-tri-
churid vaccines would seem to be more attainable
goals given the appreciation of their phylogenetic rela-
tionships, and thus, biological similarities, and would
also aim to target STHs of livestock. The latter ‘pan’
approach may also be achievable with mono or at
most bivalent vaccines as antigens that are highly con-
served within each group of target STHs, antigen(s)
likely to have very similar and important functions
for all of them, could be targeted.
Conclusions/future directions
Recombinant subunit vaccines not only oﬀer the
potential to immunologically control STHs, but
also are capable of being manufactured on a large
enough scale to vaccinate over one fourth of all
human beings and the majority of livestock in
developing regions. Studies in hookworms have
reported several recombinant immunogens with
signiﬁcant immunogenicity and protection, some
of which progressed to clinical trials. The current
best candidates in hookworms are those present
in the adult intestine with roles in digestion of
haemoglobin; those expressed in infective L3 are
at risk of inducing allergic reactions in individuals
with pre-existing IgE, and thus, should be avoided.
Studies of another family of strongylids, the stron-
gyloids, have revealed a number of immunogenic
and protective recombinant immunogens in
experimental vaccinations. But so far in the tri-
chostrongyloids of livestock, minimal success has
been achieved, likely due to the more technical
factors of recombinant protein expression and/or
puriﬁcation. There are a number of recombinant
immunogens from the ascarids that provided sign-
iﬁcant protection, some of which have been vali-
dated via RNAi to have important roles during
infection. However, all of the target ascarid anti-
gens are naturally immunodominant, abundant
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L3 surface proteins and thus, the studies in hook-
worms suggest potential issues for clinical applica-
tion of the candidate immunogens. A few
protective immunogens have been reported from
T. spiralis that may also be eﬀective against the
relatively closely related trichurids.
Although there have been many successes with
experimental vaccination using recombinant subunit
vaccines, we still are far from understanding the
mechanisms of vaccine-induced protection, which
will require a sturdy bridge between vaccinology
and immunobiology. A better understanding of the
immunobiology and mechanism(s) of protection
will lead to more potent, broad-spectrum vaccines.
Also, more technical factors need to be better
explored, such as why certain recombinant expres-
sion systems work and others do not for particular
immunogens, how many injections and what doses
per injection are optimal, which route of immuniza-
tion is optimal (i.e. parenteral or oral/intranasal) and
how long the immunological memory responses
remain protective. Furthermore, many of the pre-
clinical vaccine studies mentioned in this review
focused on laboratory models, and thus, it is
diﬃcult to extrapolate to the target animals (and
humans) as it is unclear whether the variation in
immunological and biological factors will result in
diﬀerent vaccine eﬃcacies. Better understanding
these more technical factors and integrating genom-
ics for testing higher priority target antigens will
undoubtedly result in durable vaccines to protect
our planet from these critical parasites.
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